Inventiva (IVA) 6-K 15 Oct 24 2024 Q2 Current report (foreign) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2024
Document and Entity Information
Document Type	6-K
Document Period End Date	Jun. 30, 2024
Entity Registrant Name	Inventiva S.A.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001756594

Unaudited interim condensed con

Unaudited interim condensed consolidated statement of financial position - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Noncurrent assets
Intangible assets	€ 451,000	€ 541,000
Property, plant and equipment	7,979,000	9,125,000
Deferred tax assets	210,000	225,000
Investments accounted for using the equity method	1,131,000	1,425,000
Other non-current assets	1,047,000	10,055,000
Total non-current assets	10,818,000	21,371,000
Current assets
Inventories	393,000	417,000
Trade receivables	809,000	3,807,000
Tax receivables	2,704,000	5,352,000
Other current assets	14,554,000	11,696,000
Cash and cash equivalents	10,147,000	26,918,000
Total current assets	28,608,000	48,189,000
Total assets	39,426,000	69,561,000
Shareholders' equity
Share capital	524,772	521,000
Premiums related to share capital	201,859,000	201,862,000
Reserves	(232,789,000)	(124,584,000)
Translation reserve	375,000	596,000
Net loss for the period	(49,029,000)	(110,426,000)
Shareholders' equity	(79,060,000)	(32,032,000)
Noncurrent liabilities
Long-term debt	46,846,000	32,181,000
Long-term debt - derivatives	13,569,000	10,265,000
Royalty certificates liabilities	7,263,000	6,327,000
Provisions for retirement benefit obligations	1,555,000	1,559,000
Long-term contract liabilities	76,000	70,000
Other non-current liabilities	1,032,000	1,032,000
Total non-current liabilities	70,340,000	51,434,000
Current liabilities
Shortterm debt	5,726,000	5,308,000
Trade payables	36,583,000	37,679,000
Short-term contract liabilities	3,000	6,000
Other current liabilities	5,834,000	7,165,000
Total current liabilities	48,146,000	50,158,000
Total liabilities	118,486,000	101,592,000
Total equity and liabilities	€ 39,426,000	€ 69,561,000

Unaudited interim condensed c_2

Unaudited interim condensed consolidated statement of income (loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenues and other income
Revenue	€ 41	€ 1,901
Other income	2,693	4,721
Total revenues and other income	2,734	6,622
Research and development costs	(46,822)	(54,062)
Marketing - Business development expenses	(598)	(705)
General and administrative expenses	(7,701)	(6,812)
Other operating income (expenses)	138	(44)
Net operating loss	(52,249)	(55,003)
Financial income	9,093	2,373
Financial expenses	(5,586)	(2,646)
Net financial income	3,507	(273)
Share of net loss - Equity method	(168)
Income tax	(119)	7
Net loss for the period	€ (49,029)	€ (55,269)
Basic loss per share	€ (0.94)	€ (1.31)
Diluted loss per share	€ (0.94)	€ (1.31)
Weighted average number of shares outstanding used to calculate basic loss per share	51,982,093	42,044,796
Weighted average number of shares outstanding used to calculate diluted loss per share	51,982,093	42,044,796

Unaudited interim condensed c_3

Unaudited interim condensed consolidated statement of comprehensive (income) loss € in Thousands	6 Months Ended
	Jun. 30, 2024 EUR (€)
Unaudited interim condensed consolidated statement of comprehensive (income) loss
Net loss for the period	€ (49,029)
Items that will be reclassified subsequently to profit or loss	(220)
Currency translation differences - equity method	(286)
Currency translation differences	66
Items that will not be reclassified subsequently to profit or loss	74
Remeasurement of defined benefit plans	74
Total comprehensive loss	€ (49,175)

Unaudited interim condensed c_4

Unaudited interim condensed consolidated statement of changes in shareholders' equity - EUR (€)	Share capital	Premiums related to share capital	Net profit (loss)	Translation reserves	Reserves	Total
Balance at the beginning at Dec. 31, 2022	€ 421,000	€ 173,886,000	€ (54,274,000)	€ (271,000)	€ (74,286,000)	€ 45,476,000
Net loss for the period			(55,269,000)			(55,269,000)
Remeasurement of defined benefit plans					(14,000)	(14,000)
Currency translation differences				104,000		104,000
Total comprehensive loss			(55,269,000)	104,000	(14,000)	(55,179,000)
Appropriation of net income (loss)			54,274,000		(54,274,000)
Share-based payment compensation expenses					2,046,000	2,046,000
BSA share warrants subscription premium					2,000	2,000
Treasury shares					10,000	10,000
Other					(22,000)	(22,000)
Balance at the end at Jun. 30, 2023	421,000	173,886,000	(55,269,000)	(168,000)	(126,537,000)	(7,667,000)
Balance at the beginning at Dec. 31, 2022	421,000	173,886,000	(54,274,000)	(271,000)	(74,286,000)	€ 45,476,000
Balance at the end (in shares) at Dec. 31, 2023						52,115,807
Balance at the end at Dec. 31, 2023	521,158	201,862,263	(110,426,000)	596,000	(124,584,000)	€ (32,032,000)
Net loss for the period			(49,029,000)			(49,029,000)
Remeasurement of defined benefit plans					74,000	74,000
Currency translation differences				(220,000)		(220,000)
Total comprehensive loss			(49,029,000)	(220,000)	74,000	(49,175,000)
Appropriation of net income (loss)			110,426,000		(110,426,000)
Share-based payment compensation expenses					2,238,000	2,238,000
BSA share warrants subscription premium	4,000	(4,000)			6,000	6,000
Treasury shares					(138,000)	(138,000)
Other					41,000	€ 41,000
Balance at the end (in shares) at Jun. 30, 2024						52,477,188
Balance at the end at Jun. 30, 2024	€ 524,772	€ 201,858,649	€ (49,029,000)	€ 375,000	€ (232,789,000)	€ (79,060,000)

Unaudited interim condensed c_5

Unaudited interim condensed consolidated statement of cash flows - EUR (€) € in Thousands		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Cash flows used in operating activities
Net loss for the period		€ (49,029)	€ (55,269)
Elimination of non-cash or non-operating income and expenses
Depreciation, amortization and provisions		1,878	1,138
Deferred and current taxes		22	(35)
Tax credits		(2,657)	(3,643)
Cost of debt		5,180	1,900
Sharebased compensation expense		2,238	2,046
Share of net profit of associates and joint ventures accounted for using the equity method		8
Exchange (gains) / losses		(73)	503
Fair value variation through profit and loss		(8,506)	(1,623)
Other			18
Cash flows used in operations before tax, interest and changes in working capital		(50,939)	(54,965)
Decrease / (increase) in operating and other receivables		4,075	(2,322)
Increase / (decrease) in operating and other payables		(2,409)	8,147
Decrease / (increase) in inventories		24	(28)
Tax credit received		5,333	5,220
Other	[1]	(4,426)	(1,285)
Tax, interest and changes in operating working capital		2,597	9,732
Net cash used in operating activities		(48,342)	(45,233)
Cash flows used in investing activities
Purchases of property, plant and equipment and intangible assets		(255)	(230)
Disposals of property, plant and equipment and intangible assets		90	130
Decrease / (Increase) in short-term deposit accounts		70	998
Increase / (Decrease) in other non-current financial assets		9,008	(8,600)
Net cash from (used in) investing activities		8,912	(7,702)
Cash flows used in financing activities
Capital increase net of transaction cost		6	2
Subscription of borrowings and warrants net of transaction cost		24,911
Repayment of debt		(1,177)	(1,448)
Repayment of lease liabilities		(1,173)	(707)
Net cash from (used in) financing activities		22,568	(2,153)
Net increase (decrease) in cash and cash equivalents		(16,863)	(55,087)
Cash and cash equivalents at beginning of period		26,918	86,736
Exchange gains / (losses)		92	(409)
Net cash and cash equivalents at the end of period		€ 10,147	€ 31,240
[1]Mainly include an increase in prepaid expense

Company information

Company information	6 Months Ended
	Jun. 30, 2024
Company information
Company information	Note 1. Company information 1.1 Company information Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group is designated as “Inventiva” or the “Company”). Inventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva’s American Depositary Shares (“ADSs”), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the treatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with MASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with MASH/NASH and announced that the U.S. Food and Drug Administration ("FDA") had granted the Company the status of Breakthrough Therapy and Fast Track designation. The Company initiated the pivotal Phase III trial of lanifibranor in MASH/NASH (“NATiV3”) in the second half of 2021. In March 2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and Type 2 Diabetes (“DT2”) (“LEGEND”). In the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a higher than originally projected screen failure rate resulting in slower than anticipated enrollment rate. In addition, the Company experienced slower than predicted site activation, screening and enrollment due to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the Company was unable to conduct clinical trial activities at sites originally located in Ukraine due to the war between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in Ukraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the markets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could affect the Company. In January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially accelerate enrollment and identified additional sites to help compensate for the inability to use sites in Ukraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks instead of up to seven years, reduces the number of biopsies from three to two and included a 48-week active treatment extension study. The Company expects that the changes to the clinical development plan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and compensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to patients with MASH/NASH and compensated cirrhosis. In September 2022, the Company entered into a license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., LTD (“CTTQ”), a Sino Biopharm group company, to develop and commercialize, subject to regulatory approval, lanifibranor for the treatment of MASH/NASH and other metabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan (“CTTQ Territory”). In May 2023, the Company announced that CTTQ had received the Investigational New Drug (“IND”) approval from the Chinese National Medicine Products Administration (“NMPA”) allowing CTTQ to initiate the clinical development of lanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing NATiV3 Phase III trial and is conducting a Phase I clinical pharmacology study. In the framework of its participation in the Company’s NATiV3 Phase III global clinical trials, pursuant to the terms of the agreement, CTTQ bears all costs associated with these trials conducted in the CTTQ Territory. In September 2023, the Company and Hepalys Pharma, Inc. (“Hepalys”) announced an exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the “Hepalys License Agreement”). Hepalys is a new company created by Catalys Pacific Fund II, LP (“Catalys”). Under the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to €9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical, regulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval. In parallel with the Hepalys License Agreement, the Company entered into an option agreement with Catalys to acquire 30% of the shares of Hepalys (the “Catalys Option Agreement”). The Company exercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate exercise price of ¥300 (equal to €1.90). Also on September 20, 2023, the Company entered into a shareholders agreement with Catalys and Hepalys (the “Catalys Shareholders Agreement”). Pursuant to the Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal if Hepalys receives an offer for the license or rights related to lanifibranor. In the first quarter of 2024, following a routine visit during the Company’s NATiV3 clinical trial of lanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (“SUSAR”) was reported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the Data Monitoring Committee (“DMC”) 3 On March 7, 2024, the Company announced that screening activities had resumed in American sites under central Institutional Review Board (“IRB”). The impact of the pause on the overall timeline of the trial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate, and the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial participants. On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and DT2. The Company expects the first visit of the last patient to be in the fourth quarter of 2024 and to complete randomization in the first half of 2025. Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024 and the publication of the main results for the beginning of the second half of 2026. The publication of the topline results of the part 1 of the NATiV3 trial is targeted for the second half of 2026 (versus the beginning of the second half of 2026 as previously announced). If the results of the trial confirm sufficient clinical benefit and a continued good safety profile, the Company plans to file an application for accelerated approval in the United States and conditional authorization in the European Union for the marketing of lanifibranor. The Company’s pipeline also includes odiparcil, which it was previously developing for the treatment of patients with mucopolysaccharidosis type VI (“MPS VI”), a group of rare genetic diseases. As announced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor. Based on feedback from the FDA, the Company believes there is potential for an efficient development pathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership, license or other transaction. 3 ​ 1.2 Significant events in the first half of 2024 The Company issued 3,144,654 warrants to EIB in connection with the drawdown of Tranche B (see Note 4.10 Financial debt) On January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment Bank (“ EIB EIB Tranche B Warrants th The exercise price of the EIB Tranche B Warrants is equal to €3.95 and corresponds to 95% of the volume-weighted average price of the Company's shares on the regulated market of Euronext Paris during the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024). The EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the earliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within the twelve-year period. EIB has a put option which may require the Company to repurchase all or part of the unexercised EIB Tranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn under the Finance Contract) under certain circumstances (for example, in the event of a change of control or on the maturity date of Tranche A or in the event of default). The Company (or a substitute third party) has a call option to require EIB to sell all shares and other securities of the Company, including the EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company has a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party, subject to certain terms and conditions. On the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB Tranche B Warrants at a price of €3.95 per new share, the Company could potentially receive gross proceeds of up to €12,421,383. There is no assurance that EIB will exercise any or all of the EIB Warrants or that the Company will receive any proceeds from the exercise of the warrants. The exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of Tranche B Tranche B Warrants. As of the date of authorization of the issuance of these financial statements, one EIB Tranche A Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company. The Company draws down Tranche B of €25 million under Finance Contract with EIB (see Note 4.10 Financial debt) On January 18, 2024, the Company drew down Tranche B of €25 million under the Finance Contract with EIB. After the drawdown of Tranche A in December 2022, the Company had an option to access further €25 million tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the achievement of those conditions, the Company decided to draw on Tranche B. The Company intends to use the proceeds to fund part of NATiV3. Tranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in January 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among other conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of the Finance Contract of an aggregate amount of at least €70 million (inclusive of the €18 million that was a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company, or through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with an upfront payment of at least €10 million, (iv) operational criteria based on patient enrollment and number of sites activated in the Company’s NATiV3 Phase III clinical trial of lanifibranor in patients with NASH and (v) the Company issuing EIB Tranche B Warrants (see above - The Company issued 3,144,654 warrants to EIB in connection with the drawdown of Tranche B Tranche B of €25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (warrants) at inception and the borrowing costs. On June 12, 2024, the Company and EIB amended the warrant agreement to modify the rules for adjusting the exercise ratios of the EIB Warrants. Treatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024 On February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in liver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient had been without clinical symptoms throughout the period of observation. This event has been assessed as a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial participants have also been reported in the trial. The Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients enrolled in the trial continued to receive treatment under the new liver monitoring schedule recommended by the DMC. This SUSAR is the first reported in all clinical trials with lanifibranor. On March 7, 2024, the Company received approval from the central IRB overseeing clinical research in the United States to resume screening activities in its sites. This was an important milestone as 152 sites of the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60% of the patients in the main cohort. Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024, to complete randomization in the first half of 2025 and the main results for the second half of 2026 (versus the beginning of the second half of 2026 as previously disclosed). The Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D. The LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled Phase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D. The trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10mg daily) arm. The diagnosis of non-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-invasive methods including diagnostic methods including imaging. As planned per protocol, the interim analysis was done once half of the 63 planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment. The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c (HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily) or in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26% observed in the placebo arm. The study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-PDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone or in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their hepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically significant effect on several secondary and exploratory endpoints, including liver enzymes (alanine aminotransferase (“ALT”) and aspartate aminotransferase (“AST”)), insulin resistance (HOMA-IR), HDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1) assessed by LiverMultiScan®) were assessed for the first time with lanifibranor and showed a significant effect with lanifibranor alone and in combination with empagliflozin. The study also demonstrated that patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore, these results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and subcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with empagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo. This result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose tissue. The treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily for 24 weeks appears to be well tolerated, with no safety concerns reported. Given that the primary endpoint of LEGEND was met, and statistically significant results were achieved on several key additional markers, the Company has decided to stop the recruitment as defined per protocol. More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication. Additional results from NATIVE Phase IIb clinical trial On May 13, 2024, the Company announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor. Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure. Recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH On May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH. The DMC recommended to continue the clinical trial without further modification of the protocol, as amended immediately after learning about SUSAR, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively. The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, had been without clinical symptoms throughout the period of observation and has fully recovered.

Basis of preparation and statem

Basis of preparation and statement of compliance	6 Months Ended
	Jun. 30, 2024
Basis of preparation and statement of compliance
Basis of preparation and statement of compliance	Note 2. Basis of preparation and statement of compliance 2.1. The Company has prepared these unaudited interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union and IFRS Accounting Standards as issued by the International Accounting Standard Board (“IASB”). These unaudited interim condensed consolidated financial statements as of June 30, 2024 were approved by the Board of Directors of the Company on 14 October, 2024. 2.2. Statement of compliance These unaudited interim condensed consolidated financial statements were prepared in compliance with International Accounting Standards (IAS) 34 — Interim Financial Reporting Accounting principles IFRS Accounting Standards basis adopted The accounting policies applied by the Company in the preparation of the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, are identical to those used in the annual financial statements prepared in accordance with IFRS Accounting Standards as of and for the year ended December 31, 2023, with the exception of specific provisions for the preparation of unaudited interim condensed consolidated financial statements. Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2024 The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2024 in the European Union primarily concern: - Amendment to IFRS 16 – Lease liability in a sale and leaseback - Amendment to IAS 1 – Non-current liabilities with covenants - Amendment to IAS 7 and IFRS 7 – Supplier finance arrangements Those amendments had no material impact on the Company’s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024. As of June 30, 2024, the IASB had not published any amendments that would be expected to have a material impact on the Company’s consolidated financial statements. Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable concern: - Amendments to IAS 21 – Lack of Exchangeability - Amendment to IFRS 9 and IFRS 7 – Classification and Measurement of Financial Instruments - New Standard – IFRS 18 – Presentation and Disclosure in Financial Statements - New standard – IFRS 19 Subsidiaries without Public Accountability: Disclosures These new standards, interpretations and amendments are under analysis to see if there are applicable to Inventiva. 2.3. Scope and method of consolidation ● Accounting policy In accordance with IFRS 10 Consolidated Financial Statements Subsidiaries are all entities over which the Company has control. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date such control ceases. All intercompany transactions, balances, and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries are consistent with the policies adopted by the Company. ● Consolidated entities As of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized. ​ ​ ​ ​ ​ ​ ​ ​ ​ Percent of ​ ​ ​ Date of ​ Ownership ​ ​ ​ ​ incorporation ​ Interest ​ Accounting Method INVENTIVA Inc. 01/05/2021 100 % Fully Consolidated ​ ● Interests in associates and joint ventures Hepalys is incorporated and has its principal place of business in Japan. The Company’s proportion of ownership interest is 14.6% and is the same as the proportion of voting rights held. In accordance with IAS 28 Investments in Associates and Joint Ventures , Hepalys is an associate of the Company and is accounted for using the equity method (see Note 4.4. – Investments accounted for using the equity method ). 2.4 ● Functional and presentation currency The Company’s consolidated financial statements are presented in euros, which is also the functional currency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S. dollar. All amounts presented in these notes to the consolidated financial statements are denominated in euros unless otherwise stated. ● Translation of financial statements into presentation currency The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into euros, the presentation currency, as follows: ● Assets and liabilities for each balance sheet presented are translated at the closing rate on the date of that balance sheet, ● Income and expenses for each statement of (income) loss and statement of comprehensive (income) loss are translated at average exchange rates (which is an approximate value of the exchange rate on the transaction date in the absence of significant fluctuations. Income and expenses are translated at the transaction dates if the exchange rates fluctuate significantly), and ● All resulting exchange differences are recognized in other comprehensive income. ​ ​ ​ ​ ​ ​ ​ ​ Exchange rate (USD per EUR) As of June 30, 2024 As of December 31, 2023 As of June 30, 2023 Average exchange rate for the period 1.0813 ​ 1.0803 ​ 1.0807 Exchange rate at period end 1.0705 ​ 1.1050 ​ 1.0866 ​

Accounting Principles

Accounting Principles	6 Months Ended
	Jun. 30, 2024
Accounting Principles
Accounting principles	Note 3. Accounting principles 3.1. Use of estimates and judgment The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made. There have been no significant changes in the material judgments and main estimates used by management when applying the Company’s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2023. The conflict in Ukraine and the state of war between Israel and Hamas have not led to any material changes in the estimates or judgements made by management in the preparation of the Company’s unaudited interim condensed consolidated financial statements. 3.2. In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. ● Level 2: Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. ● Level 3: Unobservable inputs for the asset or liability. The table below presents the financial assets and liabilities of the Company measured at fair value as of June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ At June 30, 2024 (in thousands of euros) Level 1 Level 2 Level 3 Financial liabilities at fair value through profit or loss ​ ​ ​ Long-term financial debt - derivatives ​ — ​ — ​ 13,569 Total liabilities — — 13,569 ​ The table below presents the financial assets and liabilities of the Company measured at fair value as of December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2023 (in thousands of euros) Level 1 Level 2 Level 3 Financial liabilities at fair value through profit or loss Long-term financial debt – derivatives — — 10,265 Total liabilities — — 10,265 ​ ​ 3.3. Seasonality of operations The Company’s operations are not subject to material seasonal fluctuations. Income tax Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year. The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes. 3.4. Going concern From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates. The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates. As of June 30, 2024, the Company had €10.1 million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 – Cash and Cash equivalents As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 - Events after the reporting period Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. This estimate is based on the Company’s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after the reporting period Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.

Notes to the interim condensed

Notes to the interim condensed consolidated statement of financial position	6 Months Ended
	Jun. 30, 2024
Notes to the interim condensed consolidated statement of financial position
Notes to the interim condensed consolidated statement of financial position	Note 4. Notes to the interim condensed consolidated statement of financial position 4.1 ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Intangible assets, gross ​ 3,947 3,926 Amortization and impairment ​ (3,496) (3,384) Intangible assets, net ​ 451 541 ​ 4.2 ​ ​ ​ ​ ​ ​ In thousands of euros ​ June 30, 2024 ​ Dec. 31, 2023 Property, plant and equipment, gross 20,376 19,840 Depreciation and impairment (12,396) (10,714) Property, plant and equipment, net 7,979 9,126 ​ As of June 30, 2024, the gross value of property, plant and equipment increased by €0.5 million mainly due to the recognition of the right of use related to the Fibroscans lease agreement for €0.4 million. Depreciation and impairment increased by €1.7 million mainly due to the depreciation of €1.2 million of the right of use and €0.3 million due to an impairment of the right of use related to Fibroscan. ​ 4.3 Inventiva S.A. and Inventiva Inc. are taxed as two separate entities and cannot apply the tax consolidation. For each entity, the deferred tax assets and deferred tax liabilities are offset in the consolidated financial statements. Deferred tax assets are recognized only when an entity has sufficient evidence that it will have a sufficient taxable benefit available to use the unused tax losses in the foreseeable future. As recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to the Inventiva S.A.’s activity, deferred tax assets were recognized on this basis on June 30, 2024 only for Inventiva Inc. 4.4 Inventiva became an equity shareholder in Hepalys with the acquisition of 1,500,000 ordinary shares on October 11, 2023. On January 15, 2024, Hepalys’s shareholders approved a capital increase of €1.6 million by issuing new shares to a new investor, NVCC. Inventiva opted not to participate in this capital increase. Consequently, the Company’s ownership in Hepalys was diluted to 14.6%. As of June 30, 2024, the Company holds 14.6% of Hepalys's shares, down from 15% ownership as of December 31, 2023. The Company analyzed its ownership of Hepalys and concluded that, as of June 30, 2024, it has a significant influence but not control or joint control of Hepalys. The significant influence is reflected through the ownership of percentage of interests held, the percentage of potential voting rights owned by the Company including the option, under the Catalys Shareholders Agreement, to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation that was exercisable as at June 30, 2024, as well as the active participation in the business of Hepalys in the framework of the Hepalys License Agreement. The investment in Hepalys is accounted for using the equity method of accounting as of June 30, 2024. The tables below provide the summarized statement of financial position of Hepalys. The disclosed information reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the reconciliation between the Hepalys statement of financial position and the carrying amount in the Company statement of financial position. ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) June 30, 2024 December 31, 2023 Intangible assets 17,217 20,278 ​ Total non ‑ current assets 17,217 20,278 ​ Other current assets 17 44 ​ Cash and cash equivalents 1,997 1,082 ​ Total current assets 2,015 1,126 ​ Deferred assets 2 41 ​ Total assets 19,233 21,444 ​ ​ ​ ​ ​ ​ ​ Capital stock 523 640 ​ Capital reserve 20,379 22,655 ​ Capital surplus-others 774 — ​ Earnings brought forward (1,018) (178) ​ Net loss for the period (1,444) (1,111) ​ Treasury Shares — (812) ​ Shareholders’ equity 19,214 21,194 ​ Total non ‑ current liabilities — — ​ Trade payables 7 237 ​ Other current liabilities 12 13 ​ Total current liabilities 19 250 ​ Total equity and liabilities 19,233 21,444 ​ ​ ​ ​ ​ ​ ​ Opening net assets 21,122 22,645 ​ Loss for the period (1,509) (879) ​ Other comprehensive income (1,964) 247 ​ Capital variations 1,566 (819) ​ Closing net assets 19,214 21,194 ​ ​ ​ ​ ​ ​ ​ Group's share in ​ 15 % 15 % (in thousands of euros) ​ Group's share 2,813 3,267 ​ Elimination of unrealised profit on downstream sales (1,718) (1,881) ​ Goodwill 37 39 ​ Carrying amount 1,131 1,425 ​ ​ 4.5 ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Long-term deposit accounts ​ — 9,000 Advance payments – non-current ​ 1,047 1,047 Accrued income ​ — — Security deposits ​ — 8 Other non ‑ current assets ​ 1,047 10,055 ​ As of June 30, 2024, long-term deposit accounts with more than a year of maturity decreased by €9.0 million, related to the early closure of a €9.0 million two-year deposit forward contract. As of June 30, 2024 and December 31, 2023, non-current advances to suppliers amounted to €1.0 million, corresponding to the advance paid under the contract research organization (“ CRO Commitments related to operational activities 4.6 ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Laboratory inventories ​ 402 426 Inventories write‑down ​ (9) (9) Inventories ​ 393 417 ​ ​ 4.7 Trade receivables Trade receivables break down as follows: ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 3 months or less 809 ​ 3,807 Between 3 and 6 months — ​ — Between 6 and 12 months — ​ — More than 12 months — ​ — Trade receivables 809 ​ 3,807 ​ The average payment period is 30 days. As of June 30, 2024, trade receivables decreased by €3.0 million mainly due to the receipt of a payment from CTTQ for the reinvoicing of specific costs related to the NATiV3 trial. Tax receivables and Other current assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 CIR and other research tax credits 2,657 5,333 Other 47 19 Tax receivables 2,704 5,352 Prepaid expenses 7,039 4,656 Short-term deposit accounts ​ — ​ 70 Current accrued income ​ 1,687 ​ 1,047 Liquidity agreement - Cash ​ 289 ​ 422 Sales tax receivable ​ 3,311 ​ 5,066 Other receivables 2,229 435 Other current assets 14,554 11,696 Other current assets and receivables 17,258 17,048 ​ As of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the amount of €2.7 million corresponding to the 2024 CIR as of June 30, 2024. Prepaid expenses, which increased by about €2.4 million, are mainly composed of costs related to the NATiV3 Phase III clinical trial. 4.8 ​ ​ ​ ​ ​ ​ Net cash and cash equivalents ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Other cash equivalents (1) 10,273 17,933 Cash at bank and at hand 1,212 8,985 Bank overdrafts ​ (1,338) ​ — Cash and cash equivalents 10,147 26,918 (1) Other cash equivalents correspond to short-term bank deposits. In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of €1.3 million as of June 30, 2024. 4.9 Share capital The share capital is set at €524,772 at June 30, 2024 divided into 52,477,188 fully authorized, subscribed and paid-up shares with a nominal value of €0.01. Share capital variation during the first six months of 2024 is set forth in the table below: In euros, except number of shares ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Premiums ​ ​ ​ ​ ​ ​ ​ ​ Share ​ related to ​ Number of ​ Nominal Date Nature of the transactions capital share capital shares value Balance at December 31, 2023 ​ ​ 521,158 201,862,263 52,115,807 0.01 3/25/2024 ​ AGA 2021 & AGA 2021 bis ​ 3,614 ​ (3,614) ​ 361,381 ​ 0.01 Balance at June 30, 2024 ​ ​ ​ 524,772 ​ 201,858,649 ​ 52,477,188 ​ 0.01 ​ Liquidity agreement On January 19, 2018, the Company entered into a liquidity agreement with Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF. This agreement with Kepler Cheuvreux, as amended in 2019, automatically renews for 12-month periods unless terminated by either party. Under the terms of the agreement, the investment services provider (“ISP”) is authorized to buy and sell the Company’s treasury shares without interference from the Company in order to ensure the liquidity of the shares on the Euronext market. The liquidity agreement with Kepler Cheuvreux was extended for a new period of 12 months from January 1, 2023, and has been renewed again for a new period of 12 months from January 1, 2024. At June 30, 2024, treasury shares acquired by the Company through its ISP, as well as the gains or losses resulting from share purchase, sale, issue and cancellation transactions during the first six months of 2024, were accounted for as a deduction from equity. Consequently, these transactions had no impact on the Company’s results. Options and share warrants (BSA and BSPCE) Share-based payments correspond to: - BSA share warrants granted to Company directors in 2017, with a subscription price set at €0.534 ; - BSA share warrants granted to Company service providers in 2018, with a subscription price set at €0.48 ; - BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at €0.18 ; - BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group LLC, and Jérémy Goldberg, a member of PG Healthcare LLC, both service providers of Inventiva, with a subscription price set at €0.29 ; - BSPCE founder share warrants granted in 2021, to Frederic Cren and Pierre Broqua, Company’s Directors; - BSA share warrants granted in 2021 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, and ISLS Consulting with a subscription price set at €2.45 ; - BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at €0.20 and an exercise price of €2.51 ; and - BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at €0.31 and an exercise price of €3.91 . BSA and BSPCE plan characteristics As of January 1, 2024, one BSPCE share warrant plan was outstanding: BSPCE 2021. The BSPCE and BSA share warrant plans are described in the note 12.3 “ Share warrants plans No new share warrants plan has been attributed in the first six months of 2024. ​ Movements in BSPCE share warrants and BSA share warrants (in number of shares issuable upon exercise) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at Jan 1, ​ ​ ​ ​ ​ Forfeited / ​ at June 30, ​ exercisable Type Grant Date (in euros) 2024 Issued Exercised Lapsed 2024 shares BSPCE - Plan 2021 ​ 04/16/2021 ​ 11.74 ​ 430,000 ​ — ​ — ​ — ​ 430,000 ​ 430,000 TOTAL BSPCE share warrants 430,000 — — — 430,000 430,000 BSA - Plan 2017 05/29/2017 6.68 130,000 — — — 130,000 130,000 BSA - Plan 2018 12/14/2018 6.07 116,000 — — — 116,000 116,000 BSA 2019 06/28/2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 bis ​ 03/09/2020 ​ 3.68 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 ter ​ 03/09/2020 ​ 3.68 ​ 36,000 ​ — ​ — ​ — ​ 36,000 ​ 36,000 BSA 2021 ​ 04/16/2021 ​ 11.74 ​ 14,333 ​ — ​ — ​ — ​ 14,333 ​ 14,333 BSA 2023 ​ 05/25/2023 ​ 2.51 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ — BSA 2023 - 2 ​ 12/15/2023 ​ 3.91 ​ 20,000 ​ ​ ​ ​ ​ ​ ​ 20,000 ​ — TOTAL BSA share warrants 346,333 — — — 346,333 316,333 Total share warrants ​ ​ ​ ​ 776,333 — — — 776,333 746,333 ​ At June 30, 2024, a total of 430,000 BSPCEs (or 430,000 shares) and 346,333 BSAs were outstanding, corresponding to a total of 776,333 shares, the maximum number of shares to be issued when all related conditions are met. Free share awards AGA free share award plans As of January 1, 2024, four free share award plans were outstanding: AGA 2021-1, AGA 2021-bis, AGA 2023-1, and AGA 2023-2. No bonus share award plan has been attributed in the first six months of 2024. Movements in AGA free shares (in number of shares issuable upon exercise) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock price ​ Outstanding ​ ​ ​ ​ ​ ​ ​ Outstanding ​ ​ ​ ​ at grant date ​ at Jan 1, ​ ​ ​ ​ ​ Forfeited / ​ at June 30, Type Grant Date (in euros) 2024 Granted Vested Lapsed 2024 AGA - Plan 2021 - 1 04/16/2021 11.30 297,599 — (296,166) (1,433) — AGA - Plan 2021 - bis 12/08/2021 12.20 65,215 — (65,215) — — AGA 2023-1 05/25/2023 2.60 300,000 300,000 — — 600,000 AGA 2023-2 ​ 12/15/2023 ​ 3.90 ​ 748,000 ​ — ​ — ​ (23,350) ​ 724,650 TOTAL free shares ​ ​ ​ ​ 1,410,814 300,000 (361,381) (24,783) 1,324,650 ​ At June 30, 2024, a total of 1,324,650 AGA bonus shares were outstanding. Following the amendment of article L. 225-197-1 II of the French Commercial Code by law no. 2023-1107 of November 29, 2023, the Board of Directors decided on 25 March 2024 to grant 300,000 free shares to Frederic Cren in substitution for the PAGUP 2023. This allocation is governed by the regulations of the AGA 2023-1 plan. Following the AGA 2021 and AGA 2021 bis acquisition period, a total of 361,381 shares were definitively acquired, resulting in a capital increase of €3,613.81. Upon the completion of the acquisition period for the AGA 2021 and AGA 2021 bis plans, a total of 361,381 shares were acquired, resulting in a capital increase of €3,613.81. The free share award plan is described in the Note 12.4 “Bonus share award plans” of the annual consolidated financial statements for the year ended on December 31, 2023. Share-based compensation expense with respect to AGA bonus shares and BSA share warrants totaled €2.2 million for the six months ended June 30, 2024, compared to €2.0 million for the six months ended June 30, 2023. They are recognized in personnel costs (see Note 5.2 – Operating expenses ​ Performance units (“PAGUP”) As of January 1, 2024, one performance units plan was outstanding: PAGUP 2023. No performance units award plan has been attributed in the first six months of 2024. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reference Outstanding ​ ​ ​ Outstanding Number of ​ ​ Grant ​ price (in ​ at Jan 1, ​ ​ ​ ​ ​ ​ ​ at June 30, ​ exercisable Type ​ Date ​ euros) ​ 2024 ​ Issued ​ Exercised ​ Convert AGA ​ 2024 ​ shares PAGUP 2023 ​ 05/25/2023 ​ 2.60 ​ 300,000 ​ — ​ — ​ (300,000) ​ — ​ — TOTAL PAGUP ​ ​ ​ ​ ​ 300,000 ​ — ​ — ​ (300,000) ​ — ​ — ​ At June 30, 2024, no PAGUP shares were outstanding. Following the changes introduced by the French law no.2023-1107, the PAGUP 2023 granted on May 25, 2023 can be converted into AGAs. On March 25, 2024, the Board of Directors converted 300,000 free shares (governed by the AGA 2023-1 regulations) to Frédéric Cren, thereby lapsing the 300,000 PAGUP 2023. The performance units plan is described in the Note 12.5 “Performance units” of the annual consolidated financial statements for the year ended on December 31, 2023. 4.10 ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Bank borrowings 42,509 27,206 Derivatives instruments ​ 13,569 ​ 10,265 Other loans and similar borrowings (1) 4,302 3,719 Lease liabilities 5,761 6,565 Royalty certificates liabilities ​ 7,263 ​ 6,327 Total debt 73,404 54,082 (1) include accrued interests. Movements in the period break down as follows: ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 January 1, 2024 54,083 ​ 44,390 Subscription of derivatives instruments (2) ​ 11,809 ​ — Subscription of bank borrowings (1)(2) ​ 13,102 ​ — Subscription of lease liabilities 345 ​ 3,706 Issue of royalty certificates ​ — ​ 5,100 Repayment of bank borrowings (1,177) ​ (2,485) Repayment of lease liabilities (1,173) ​ (1,612) Interests on royalty certificates ​ 936 ​ 1,227 Capitalized interest 3,961 ​ 3,405 Change in fair value of derivatives instruments (2) (8,506) ​ 389 Exchange rate change 24 ​ (38) June 30, 2024 73,404 ​ 54,083 (1) Net proceed (2) EIB’s loan and warrants. ​ French state-guaranteed loan (“PGE”) and equity recovery loans (“PPR”) In May 2020, the Company entered into three credit agreements pursuant to which it received €10.0 million in the form of state-guaranteed loans ( Prêts Garantis par l’Etat In June 2022, the Company entered into three loan agreements with a syndicate of French banks for a total amount of €5.3 million. One loan agreement was part of a state-guaranteed PGE loan facility with Bpifrance and the other two loan agreements were part of a stimulus economic plan ( Prêts Participatifs Relance The PGE loan granted by Bpifrance in 2022 is guaranteed up to 90% by the French government with an initial term of twelve months. In May 2023, the Company exercised the option to extend the maturity to align with the 2020 PGE, until May 2026. The two PPR loans are guaranteed predominantly by the French government and feature an eight-year financing period and a four-year repayment period. The PGE repayments in the first six months of 2024 amounted to €1.2 million. Credit facility agreement with the European Investment Bank On May 16, 2022, the Company entered into the Finance Contract with the EIB for up to €50 million, divided into two tranches of €25 million each. ● On December 8, 2022, the Company received the disbursement of Tranche A. Capitalized interest for Tranche A is 8% and repayment is due in December 2026, four years after its disbursement. ● On January 18, 2024, the Company received the disbursement of Tranche B (see Note 1.2. – Significant events in the first six months of 2024 ). Capitalized interest for Tranche B is 7% and repayment is due in January 2027, three years after its disbursement. The Finance Contract may, in certain circumstances, be prepaid, in whole or in part, for a prepayment fee, either at the election of the Company or as a result of EIB’s demand following certain prepayment events, including a change of control or change in senior management of the Company. Subject to certain terms and conditions, upon the occurrence of usual events of default (i.e., including payment default, misrepresentation, cross default), EIB may demand immediate repayment by the Company of all or part of the outstanding loan. As of June 30, 2024 there was no demand of reimbursement of the outstanding loan. Tranche A of €25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of €0.1 million. The amortized cost of the loan is €15.4 million on December 31, 2023, and is € 21.1 million on June 30, 2024, with an effective interest rate of 21.9%. The fair value of the loan as of June 30, 2024, amount to €20.6 million, with a market rate of 22.9%. Tranche B of €25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of €0.1 million. The amortized cost of the loan is €15.0 million on June 30, 2024, with an effective interest rate of 32.7%. The fair value of the loan as of June 30, 2024, amount to €14.7 million, with a market rate of 33.2%. The capitalized interest for both Tranche A and Tranche B in the period amounted to €4.0 million. Derivatives On July 1, 2022, in connection with the Finance Contract (see section above “Credit facility agreement with the European Investment Bank”), the Company entered into a warrant agreement as a condition to the funding of the two tranches of the credit facility. Each EIB Warrant has a subscription price of €0.01 and gives the right to subscribe to one share. The number of EIB Warrants issued to EIB was determined based on (i) the aggregate amount raised by the Company through one or more equity offerings, or through upfront or milestone payments, from the date of the Finance Contract to the time of the disbursement of the relevant tranche, and (ii)(a) the average price per share paid for the Company’s shares in its most recent qualifying equity offering or (ii)(b) for Tranche A only, in case of no qualifying equity offering, the volume weighted average price per share of the Company over the last 180 calendar days. The EIB Warrants have a maturity of twelve years and are exercisable following the earliest to occur of (i) a change of control event, (ii) the maturity date of Tranche A, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by the EIB under the Finance Contract. The EIB Warrants shall automatically be deemed null and void if they are not exercised within the twelve-year period. Each EIB Warrant will entitle EIB to one ordinary share of the Company in exchange for the exercise price (subject to anti-dilutive provisions). However, the exercise ratio of EIB Tranche A warrants has been adjusted on December 31, 2023 following the September 5, 2023 capital increase; One EIB Tranche A Warrant entitles its holder to subscribe for 1.20 ordinary shares in the Company. EIB is entitled to a put option at its intrinsic value to require the Company to buy back the exercisable EIB Warrants not yet exercised in certain of these occurrences. On November 28, 2022, the Company issued 2,266,023 EIB Tranche A Warrants to EIB, in accordance with the terms of the 25th resolution of the Combined General Shareholders' Meeting of May 19, 2022 and Article L. 225-138 of the French Commercial Code, as a condition to the financing of Tranche A, representing approximately 4.7% of the Company’s share capital as of June 30, 2024. The exercise price of the EIB Tranche A Warrants is €4.0152, if and when they may be exercised. The potential gross proceeds if all EIB Tranche A Warrants were exercised would amount to €9.1 million. The transactions costs for the issuance of the EIB Tranche A Warrants amounted to €56 thousands. On January 4, 2024, the Company issued 3,144,654 EIB Tranche B Warrants to EIB, representing approximately 5.2% of the Company’s share capital as of June 30, 2024, in accordance with the terms of the 6 th The EIB Warrants do not meet the “fixed for fixed” criteria (non-cash settlement option which may result in exchanging a variable number of shares for a variable price) and are accounted for as standalone derivative instruments. The Company’s put options meet the definition of a derivative that are valued with the EIB Warrants. The warrant agreement includes a put option: EIB may request the Company to buy back the EIB Warrants in cash. In this context the purchase price will be defined as the difference between the volume weighted average of the trading price of the ordinary shares over the last 90 trading days and the strike price. The amount is capped, and EIB may exercise the EIB Warrants for which they did not exercise the put option. At inception, the financial debts are split between i) a debt component accounted for at amortized cost, and ii) a premium corresponding to the initial fair value of attached EIB Warrants (then remeasured at fair value through profit and loss) including a component corresponding to the put options. Valuation approach The fair value of the EIB Warrants has been estimated based on a Longstaff Schwartz approach, including the put option and the attached cap. This approach enables the estimation of the value of American options (that may be exercised during a specific period of time) with complex way of exercise (the warrant holder may exercise the warrants on the market based on the Company’s share price or exercise the put option based on the 90 days average share price of the Company). The Longstaff Schwartz approach is also based on the value of the underlying equity instrument at the valuation date, the volatility observed on the historical share price of the Company, and the contractual lifespan associated equity instruments. The hypothesis and results are detailed in the following tables: ​ ​ ​ ​ ​ ​ ​ BSA 2022 BSA 2024 Grant date 11/28/2022 ​ 01/04/2024 Expiration date 11/28/2034 ​ 01/04/2036 Number of BSA issued 2,266,023 ​ 3,144,654 Number of shares per BSA 1 ​ 1 Subscription premium price per share (€) 0.01 ​ 0.01 Exercise price per share (€) 4.02 ​ 3.95 Valuation method Longstaff Schwartz ​ Longstaff Schwartz ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of November 28, 2022 ​ ​ ​ EIB Tranche A Warrants ​ (Grant Date) ​ As of December 31, 2023 ​ As of June 30, 2024 Number of BSA outstanding 2,266,023 2,266,023 ​ 2,266,023 ​ Number of shares per BSA ​ 1.00 ​ 1.20 ​ 1.27 ​ Stock price (€) 4.13 4.10 ​ 2.79 ​ Maturity (years) 12 10.9 ​ 10.4 ​ Volatility 68 % 62 % 59.6 % Cap of the put option (m€) 25.0 25.0 ​ 25.0 ​ Risk free rate Euribor 6M Euribor 6M ​ Euribor 6M ​ Expected dividends — — ​ — ​ Fair Value (k€) 9,469 10,266 ​ 6,738 ​ Unit fair value (€) 4.18 4.53 ​ 2.97 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of January 4, 2024 ​ ​ EIB Tranche B Warrants ​ (Grant Date) ​ As of June 30, 2024 ​ Number of BSA outstanding 3,144,654 3,144,654 ​ Number of shares per BSA ​ 1.00 ​ 1.00 ​ Stock price (€) 4.12 2.79 ​ Maturity (years) 12 11.5 ​ Volatility 62 % 59.6 % Cap of the put option (m€) 25.0 25.0 ​ Risk free rate Euribor 6M Euribor 6M ​ Expected dividends — — ​ Fair Value (k€) 11,809 ​ 6,830 ​ Unit fair value (€) 3.76 2.17 ​ ​ Lease liabilities Lease liabilities amount to €5.8 million as of June 30, 2024, and decreased by €0.8 million compared to December 31, 2023. The lease liabilities are recognized each time a new Fibroscans is leased, on a period of three The breakdown between long-term and short-term debt is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ Less than Between Between More than In thousands of euros Total ​ 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 42,509 ​ 3,229 36,164 2,225 890 Derivatives 13,569 ​ — 13,569 — — Other loans ​ 4,302 ​ 42 ​ 4,260 ​ — ​ — Lease liabilities ​ 5,761 ​ 2,455 ​ 3,306 ​ — ​ — Royalty certificates liabilities ​ 7,263 ​ — ​ — ​ — ​ 7,263 Total debt 73,404 ​ 5,726 57,299 2,225 8,153 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dec. 31, 2023 ​ ​ Less than Between Between More than In thousands of euros ​ Total ​ 1 year ​ 1 and 3 years ​ 3 and 5 years ​ 5 years Bank borrowings 27,206 ​ 2,928 4,872 17,848 1,558 Derivatives ​ 10,265 ​ — ​ — ​ 10,265 ​ — Other loans and similar borrowings 3,719 ​ 82 — 3,636 — Lease liabilities ​ 6,565 ​ 2,298 ​ 4,267 ​ — ​ — Royalty certificates liabilities 6,327 ​ — — — 6,327 Total debt 54,082 ​ 5,308 9,140 31,749 7,885 ​ The maturity of long-term debt and of short-term borrowings and debt is determined according to contractual repayment terms as of June 30, 2024 and December 31, 2023. Royalty Certificates liabilities On August 31, 2023, the Company announced the issuance of the royalty certificates (“2023 Royalty Certificates”) for an aggregate amount of €5.1 million. The 2023 Royalty Certificates are accounted at the inception at the fair value (€5.1 million on August 31, 2023), and then at the amortized cost (€7.3 million on June 30, 2024 vs. €6.3 million on December 31, 2023) with an effective interest rate of 31.9%. Fair value as of June 30, 2024 On June 30, 2024, the fair value of the 2023 Royalty Certificates, calculated using discounted cash flow approach, amounts to €9.1 million. The fair value corresponds to the net present value of royalties, which depend on assumptions made by the Company with regards to the probability of success of its studies, the markets sales of lanifibranor and the discount rate (27.9%). The discount rate has been estimated based on a reconciliation between the Company’s business plan and the Company’s market capitalization as of June 30, 2024. 4.11 ​ The Company has no provisions as of June 30, 2024, and December 31, 2023. ​ 4.12 Retirement benefit obligations are determined based on the rights set forth in the national collective bargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in accordance with IAS 19 – Employee Benefits Net provision The provision recorded in respect of defined benefit schemes at the end of each reporting period is shown in the table below: ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Retirement benefit obligations ​ 1,555 ​ 1,559 Total obligation 1,555 1,559 ​ Given the absence of plan assets at June 30, 2024 and December 31, 2023, the total amount of the provision corresponds to the estimated obligation at those dates. Changes in the net provision Changes in the provision recorded in respect of defined benefit schemes break down as follows: ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Provision at beginning of period (1,559) ​ (1,234) Expense for the period (70) ​ (228) Actuarial gains or losses recognized in other comprehensive income 74 ​ (97) Provision at end of period (1,555) ​ (1,559) ​ Breakdown of expense recognized for the period ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Service cost for the period (104) (183) Interest cost for the period (25) (46) Benefits for the period 59 — Total (70) (228) ​ 4.13 Other current and non-current liabilities Other non-current liabilities As of June 30, 2024 and December 31, 2023 non-current liabilities amount to €1.0 million related to an agreement with CTTQ dated December 20, 2023 pursuant to which CTTQ paid the Company an advance for certain costs related to the NATiV3 clinical trial that the Company will incur and reinvoice to CTTQ. Other current liabilities ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Employee‑related payables 1,739 1,869 Accrued payroll and other employee-related taxes 1,801 1,540 Sales tax payables 2,140 3,569 Other accrued taxes and employee-related expenses 142 164 Other miscellaneous payables 12 23 Other current liabilities 5,834 7,165 ​ No discounting has been performed on other current liabilities as their maturity is less than one year at the end of the period. Accrued payroll and other employee-related taxes mainly relate to payables to social security and employee-benefit organizations such as URSSAF, KLESIA and APGIS for the first half of 2024. Other accrued taxes and employee-related expenses concern provisions for payroll taxes, such as professional training charges, apprenticeship tax, the employer’s contribution to construction investment in France and the payroll tax. ​ ​ 4.14 ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Trade payables ​ 36,583 37,679 Short-term contract liabilities ​ 3 ​ 6 Other current liabilities ​ — — Trade payables and other current liabilities ​ 36,586 37,685 ​ No calculations have been made to discount trade payables to present value as payment is due within one year at the end of the reporting period. ​ Trade payables Trade payables break down as follows: ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Due in 30 days ​ 26,217 24,995 Due in 30-60 days ​ 10,362 12,684 Due in more than 60 days ​ 4 — Trade payable ​ 36,583 37,679 ​ As of June 30, 2024, trade payables mainly included accrued liabilities for €24.0 million of which €20.2 million relate to scientific projects. As of June 30, 2024, trade payables decreased by €1.1 million compared to December 31, 2023. Trade payables, which depend on the frequency of CRO invoicing, were relatively stable (down by less than 3%). ​ 4.15 The table below presents the carrying amount of financial assets and liabilities by IFRS 9 accounting category: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ ​ ​ Financial ​ ​ ​ ​ ​ ​ ​ ​ Book value ​ assets/liabilities ​ Financial ​ ​ ​ ​ ​ ​ on the ​ carried at ​ assets ​ Liabilities ​ ​ ​ ​ statement ​ fair value ​ carrieds at ​ carried at ​ ​ ​ ​ of financial ​ through ​ amortized ​ amortized ​ ​ Financial assets position profit or loss cost cost Fair value Long-term accrued income ​ — — — — — Long-term deposit accounts ​ — ​ — ​ — ​ — ​ — Advance payment ​ 1,047 ​ — ​ 1,047 ​ — ​ 1,047 Current accrued income ​ 1,687 — 1,687 — 1,687 Short-term deposit accounts ​ — — — — — Trade receivables ​ 809 ​ — ​ 809 ​ — ​ 809 Other receivables ​ 2,518 — 2,518 — 2,518 Cash and cash equivalents ​ 10,147 — 10,147 — 10,147 Total ​ 16,208 — 16,208 — 16,208 ​ ​ ​ ​ ​ ​ ​ Financial liabilities ​ ​ ​ ​ ​ ​ Long-term debt (1) ​ 46,846 — — 46,846 45,994 Derivative instruments ​ 13,569 13,569 — — 13,569 Royalty certificates liabilities ​ 7,263 ​ — ​ — ​ 7,263 ​ 9,050 Short-term debt ​ 5,726 — — 5,726 5,726 Trade payables ​ 36,583 ​ — ​ — ​ 36,583 ​ 36,583 Other miscellaneous payables ​ 12 ​ — ​ — ​ 12 ​ 12 Total ​ 109,998 ​ 13,569 ​ — ​ 96,429 ​ 110,933 (1) See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dec. 31, 2023 ​ ​ Financial ​ ​ ​ ​ ​ Book Value ​ assets/liabilities ​ Financial ​

Notes to the interim condense_2

Notes to the interim condensed consolidated statement of (income) loss	6 Months Ended
	Jun. 30, 2024
Notes to the interim condensed consolidated statement of (income) loss
Notes to the interim condensed consolidated statement of (income) loss	Note 5. Notes to the interim condensed consolidated statement of (income) loss ​ 5.1 Revenues and other income For the six months ended June 30, 2024, and June 30, 2023 ​ ​ ​ ​ ​ ​ Operating income ​ Six months ended In thousands of euros June 30, 2024 June 30, 2023 Revenue 41 ​ 1,901 Total revenue 41 ​ 1,901 Tax credits 2,630 ​ 3,631 Subsidies 5 ​ 3 Other 58 ​ 1,087 Other income 2,693 ​ 4,721 Total revenue and other income 2,734 ​ 6,622 ​ Other operating income The Research Tax Credit (“CIR”) generated over the first six months of the fiscal year amounts to €2.7 million in 2024 as in 2023. As of June 30, 2023, other operating income are composed of: ● The R&D Tax Research Credit from Inventiva Inc amounting to €1.0 million, compared to €0.8 million in tax income as of June 30, 2024; ● The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to €0.3 million as of June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3, and the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to €0.7 million, compared to €2.6 million in CTTQ re-invoicing as of June 30, 2024, accounted as a reduction in research and development expenses. 5.2 Operating expenses For the six months ended June 30, 2024 and June 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and ​ Marketing – ​ General and ​ ​ Six months ended June 30, 2024 ​ development ​ Business ​ administrative ​ ​ In thousands of euros costs development expenses Total Disposables (887) — — (887) Energy and liquids (447) — — (447) Patents (643) — — (643) Studies (34,073) — — (34,073) Maintenance (526) — — (526) Fees (118) (2) (2,675) (2,795) IT systems (405) (6) (33) (444) Support costs (including taxes) — — (375) (375) Personnel costs (7,637) (153) (2,600) (10,391) Depreciation, amortization and provisions (1,732) — (122) (1,854) Insurances ​ — ​ — ​ (921) ​ (921) Other operating expenses (352) (437) (975) (1,764) Total operating expenses (46,822) (598) (7,701) (55,122) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and ​ Marketing – ​ General and ​ ​ Six months ended June 30, 2023 ​ development ​ Business ​ administrative ​ ​ en milliers d'euros costs development expenses Total Disposables (943) — — (943) Energy and liquids (479) — — (479) Patents (257) — — (257) Studies (42,847) — — (42,847) Maintenance (459) — — (459) Fees (61) — (1,884) (1,945) IT systems (440) (9) (50) (498) Support costs (including taxes) — — (343) (343) Personnel costs (7,065) (126) (2,347) (9,538) Depreciation, amortization and provisions (1,061) — (104) (1,166) Insurances ​ — ​ — ​ (1,121) ​ (1,121) Other operating expenses (450) (570) (964) (1,985) Total operating expenses (54,062) (705) (6,812) (61,580) ​ Personnel costs and headcount ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketing - ​ ​ ​ ​ Research and ​ Business ​ General and ​ ​ Six months ended June 30, 2024 ​ development ​ development ​ administrative ​ ​ In thousands of euros ​ costs ​ expenses ​ expenses ​ Total Wages, salaries and similar costs (4,824) (120) (1,237) (6,181) Payroll taxes (1,312) (10) (563) (1,886) Provisions for retirement benefit obligations (51) — (35) (86) Share-based payments (1,450) (24) (765) (2,238) Total personnel costs (7,637) (153) (2,600) (10,391) ​ The Company has 123 employees as of June 30, 2024, of which 112 are employed by Inventiva S.A. and 11 are employed by Inventiva Inc. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketing - ​ ​ ​ ​ Research and ​ Business ​ General and ​ ​ Six months ended June 30, 2023 ​ development ​ development ​ administrative ​ ​ In thousands of euros costs expenses expenses Total Wages, salaries and similar costs (4,399) (104) (1,191) (5,694) Payroll taxes (1,222) (10) (476) (1,708) Provisions for retirement benefit obligations (61) — (29) (90) Share-based payments (1,383) (13) (650) (2,046) Total personnel costs (7,065) (126) (2,347) (9,538) ​ The Company had 117 employees as of June 30, 2023, including 105 people employed by Inventiva S.A. and 12 people employed by Inventiva Inc. ​ 5.3 Other operating income and expenses break down as follows: ​ ​ ​ ​ ​ ​ ​ Six months ended In thousands of euros June 30, 2024 June 30, 2023 Other operating income ​ 160 ​ — Other operating expenses ​ (22) ​ (44) Other operating income and expenses 138 ​ (44) ​ 5.4 ​ For the six months ended June 30, 2024 and June 30, 2023 ​ ​ ​ ​ ​ ​ ​ Six months ended In thousands of euros June 30, 2024 June 30, 2023 Income from cash equivalents 430 ​ 564 Foreign exchange gains 157 ​ 187 Gain on fair value variation ​ 8,506 ​ 1,623 Total financial income 9,093 ​ 2,373 Interest cost (5,218) ​ (1,941) Foreign exchange losses ​ (323) ​ (683) Other financial expenses (46) ​ (23) Total financial expenses (5,586) ​ (2,646) Net financial income 3,507 ​ (273) ​ In the first six months of 2024, financial income is mainly composed of a €8.5 million change in fair value of the EIB Warrants issued in connection with Tranches A and B. Financial expenses mainly include exchange losses, financial interests related to PGE and PPR credit agreements and the financing agreement with the EIB, and financial interests related to lease liabilities. ​ 5.5 The tables below provide the summarized statement of income (loss) for the associate Hepalys. The information disclosed reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the reconciliation between Hepalys' loss and the share of net loss recognized in the Company statement of financial position. ​ ​ ​ ​ ​ (in thousands of euros) For the period started January 1, 2024, to June 30, 2024 Research and development costs (51) ​ General and administrative expenses (1,475) ​ Net operating loss (1,526) ​ Financial income 20 ​ Financial expenses (3) ​ Net financial income 17 ​ Income (expense) tax — ​ Net loss for the period (1,509) ​ Exchange difference on translation of foreign operations (1,964) ​ Items that will be reclassified subsequently to profit or loss (3,473) ​ Total comprehensive loss (3,473) ​ Group's share in 14.64 % Share of net profit 235 ​ Elimination of downstream sales (66) ​ Share of net profit - Equity method 168 ​ ​ In 2024, Hepalys did not generate any sales. 5.6 The income tax calculation for interim periods is set out in Note 3.3 – Specific disclosure requirements for unaudited interim financial statements. As the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered unlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December 31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A. The €119 thousand income tax recorded was related Inventiva Inc. 5.7 Basic and diluted loss per share ​ Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the six-month period ended June 30, 2024. For the six months ended June 30, 2024 and June 30, 2023 ​ ​ ​ ​ ​ ​ ​ Six months ended ​ June 30, 2024 June 30, 2023 Net loss for the period (49,029) ​ (55,269) Weighted average number of shares outstanding used to calculate basic/diluted loss per share (1) 51,982,093 ​ 42,044,796 Basic/diluted loss per share (0.94) ​ (1.31) (1) In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2024 and 2023 ​ As a loss was recorded in the first six months of 2024 and 2023, diluted earnings (loss) per share are the same as basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs, AGAs and PAGUP) are not included as their effects would be anti-dilutive.

Other financial information

Other financial information	6 Months Ended
	Jun. 30, 2024
Other financial information
Other financial information	Note 6. Other financial information 6.1 Commitments related to operational activities Obligations under the terms of subcontracting agreements In the ordinary course of its business, the Company enters into agreements with CROs for clinical trials, as well as with contract manufacturing organizations (“CMOs”) for clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products for operating purposes. The Company’s agreements generally provide for termination with specified periods of advance notice. Such agreements are generally cancellable contracts and are not included in the description of the Company’s contractual obligations and commitments. Commitments given and received ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 December 31, 2023 CRO 1 175,461 ​ 183,366 CMO 6,846 ​ 5,733 Lease 7,592 ​ 8,595 Others 20,361 ​ 23,442 Total commitments given 210,261 ​ 221,136 Agreements concerning the provision of facilities 296 ​ 260 Total commitments received 296 ​ 260 1 Including CRO with Pharmaceutical Research Associates B.V. CRO Contract with Pharmaceutical Research Associates Group B.V. In April 2021, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into an agreement, with retroactive effect in January 2021, with PRA, acting as a CRO. The contract aims to support the regulatory approval of lanifibranor in adult patients in Europe and in the United States. The Company also entered into a CRO agreement with PRA in connection with the LEGEND Phase IIa clinical trial, effective January 14, 2022. Under the terms of the agreement, PRA will conduct a clinical trial to evaluate the benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2 inhibitor, in patients with T2D and non-cirrhotic MASH/NASH. The commitment to PRA under this agreement amounts to an aggregate of €13.3 million. On June 26, 2023, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into a new amendment to the April 2021 agreement with retroactive effect in January 2021 with PRA. The amendment updates the provisions relating to study information following changes to the trial protocol. In June 2024, the Company entered into a new amendment, the new commitment amount to PRA is €254.3, with a bonus or malus will decrease from €3.4 million to €0.7 million in 2026. The commitment also includes €20.2 million to be paid by CTTQ. As of June 30, 2024, the amount remaining to be paid under the contract is €158.6 million. 6.2. No other new material transactions were entered into with related parties of the Company during the first six months of 2024. 6.3 Through its business activities, the Company is exposed to various types of financial risk: foreign exchange risk, credit risk and liquidity risk. The financial risks are those described in the financial statements prepared in accordance with IFRS for the year ended December 31, 2023, as updated for risks regarding liquidity which are described in the Note 3.4 — Going Concern 6.4 Update on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH. On July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3. The first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024, and topline results are expected at the beginning of the second half of 2026. The Company’s patent portfolio strengthened with new a patent secured in Japan that that provides intellectual property rights on protects the potential use of lanifibranor for the treatment of patients with cirrhosis until 2039, excluding any potential patent term adjustments or extensions that may provide additional protection until 2043. Issuance of royalty certificates On July 18, 2024, the Company announced the issuance of 201 royalty certificates (the “ 2024 Royalty Certificates Approving of patent application On July 25, 2024 the Company announced that the Japan Patent Office (“JPO”) approved Inventiva’s patent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients with cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent term adjustments or extensions that may provide additional protection. Financing in three tranches for a maximum amount of €348 million The Company announced the following financing on 14 October 2024 structured in three tranches: (i) the issuance , through a capital increase without preferential subscription rights reserved to a specific category of beneficiaries (“ à catégorie de personnes T1 New Shares T1 BSAs (ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (“ à personne dénommée T1bis New Shares (iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (“ à personne dénommée ABSAs T2 New Share T3 BSA The subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024, and the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October 17, 2024, subject to the absence of any material adverse event between the signing of the agreements and the settlement-delivery of the T1 New Shares and the T1 BSA. Amendment to the exclusive license and collaboration agreement with CTTQ On October 11, 2024, the Company has entered into an amendment (the “ Amendment CTTQ Fund Raising

Accounting Principles (Policies

Accounting Principles (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Principles
Use of estimates and judgment	3.1. Use of estimates and judgment The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made. There have been no significant changes in the material judgments and main estimates used by management when applying the Company’s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2023. The conflict in Ukraine and the state of war between Israel and Hamas have not led to any material changes in the estimates or judgements made by management in the preparation of the Company’s unaudited interim condensed consolidated financial statements.
Fair value measurement	3.2. In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. ● Level 2: Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. ● Level 3: Unobservable inputs for the asset or liability. The table below presents the financial assets and liabilities of the Company measured at fair value as of June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ At June 30, 2024 (in thousands of euros) Level 1 Level 2 Level 3 Financial liabilities at fair value through profit or loss ​ ​ ​ Long-term financial debt - derivatives ​ — ​ — ​ 13,569 Total liabilities — — 13,569 ​ The table below presents the financial assets and liabilities of the Company measured at fair value as of December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2023 (in thousands of euros) Level 1 Level 2 Level 3 Financial liabilities at fair value through profit or loss Long-term financial debt – derivatives — — 10,265 Total liabilities — — 10,265 ​
Specific disclosure requirements for unaudited interim financial statements	3.3. Seasonality of operations The Company’s operations are not subject to material seasonal fluctuations. Income tax Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year. The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes.
Going concern	3.4. Going concern From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates. The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates. As of June 30, 2024, the Company had €10.1 million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 – Cash and Cash equivalents As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 - Events after the reporting period Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. This estimate is based on the Company’s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after the reporting period Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.

Basis of preparation and stat_2

Basis of preparation and statement of compliance (Tables)	6 Months Ended
	Jun. 30, 2024
Basis of preparation and statement of compliance
Schedule of subsidiaries	As of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized. ​ ​ ​ ​ ​ ​ ​ ​ ​ Percent of ​ ​ ​ Date of ​ Ownership ​ ​ ​ ​ incorporation ​ Interest ​ Accounting Method INVENTIVA Inc. 01/05/2021 100 % Fully Consolidated
Schedule of exchange rates	​ ​ ​ ​ ​ ​ ​ ​ Exchange rate (USD per EUR) As of June 30, 2024 As of December 31, 2023 As of June 30, 2023 Average exchange rate for the period 1.0813 ​ 1.0803 ​ 1.0807 Exchange rate at period end 1.0705 ​ 1.1050 ​ 1.0866 ​

Accounting Principles (Tables)

Accounting Principles (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Principles
Schedule of financial assets and liabilities measured at fair value	​ ​ ​ ​ ​ ​ ​ ​ At June 30, 2024 (in thousands of euros) Level 1 Level 2 Level 3 Financial liabilities at fair value through profit or loss ​ ​ ​ Long-term financial debt - derivatives ​ — ​ — ​ 13,569 Total liabilities — — 13,569 ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2023 (in thousands of euros) Level 1 Level 2 Level 3 Financial liabilities at fair value through profit or loss Long-term financial debt – derivatives — — 10,265 Total liabilities — — 10,265

Notes to the interim condense_3

Notes to the interim condensed consolidated statement of financial position (Tables)	6 Months Ended
	Jun. 30, 2024
Notes to the interim condensed consolidated statement of financial position
Schedule of intangible assets	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Intangible assets, gross ​ 3,947 3,926 Amortization and impairment ​ (3,496) (3,384) Intangible assets, net ​ 451 541
Schedule of property, plant and equipment	​ ​ ​ ​ ​ ​ In thousands of euros ​ June 30, 2024 ​ Dec. 31, 2023 Property, plant and equipment, gross 20,376 19,840 Depreciation and impairment (12,396) (10,714) Property, plant and equipment, net 7,979 9,126
Schedule of investment in Hepalys is accounted for using the equity method of accounting	​ ​ ​ ​ ​ ​ ​ (in thousands of euros) June 30, 2024 December 31, 2023 Intangible assets 17,217 20,278 ​ Total non ‑ current assets 17,217 20,278 ​ Other current assets 17 44 ​ Cash and cash equivalents 1,997 1,082 ​ Total current assets 2,015 1,126 ​ Deferred assets 2 41 ​ Total assets 19,233 21,444 ​ ​ ​ ​ ​ ​ ​ Capital stock 523 640 ​ Capital reserve 20,379 22,655 ​ Capital surplus-others 774 — ​ Earnings brought forward (1,018) (178) ​ Net loss for the period (1,444) (1,111) ​ Treasury Shares — (812) ​ Shareholders’ equity 19,214 21,194 ​ Total non ‑ current liabilities — — ​ Trade payables 7 237 ​ Other current liabilities 12 13 ​ Total current liabilities 19 250 ​ Total equity and liabilities 19,233 21,444 ​ ​ ​ ​ ​ ​ ​ Opening net assets 21,122 22,645 ​ Loss for the period (1,509) (879) ​ Other comprehensive income (1,964) 247 ​ Capital variations 1,566 (819) ​ Closing net assets 19,214 21,194 ​ ​ ​ ​ ​ ​ ​ Group's share in ​ 15 % 15 % (in thousands of euros) ​ Group's share 2,813 3,267 ​ Elimination of unrealised profit on downstream sales (1,718) (1,881) ​ Goodwill 37 39 ​ Carrying amount 1,131 1,425 ​
Schedule of other non current assets	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Long-term deposit accounts ​ — 9,000 Advance payments – non-current ​ 1,047 1,047 Accrued income ​ — — Security deposits ​ — 8 Other non ‑ current assets ​ 1,047 10,055
Schedule of inventories	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Laboratory inventories ​ 402 426 Inventories write‑down ​ (9) (9) Inventories ​ 393 417
Schedule of trade receivables and others break down	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 3 months or less 809 ​ 3,807 Between 3 and 6 months — ​ — Between 6 and 12 months — ​ — More than 12 months — ​ — Trade receivables 809 ​ 3,807
Schedule of other current assets and receivables	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 CIR and other research tax credits 2,657 5,333 Other 47 19 Tax receivables 2,704 5,352 Prepaid expenses 7,039 4,656 Short-term deposit accounts ​ — ​ 70 Current accrued income ​ 1,687 ​ 1,047 Liquidity agreement - Cash ​ 289 ​ 422 Sales tax receivable ​ 3,311 ​ 5,066 Other receivables 2,229 435 Other current assets 14,554 11,696 Other current assets and receivables 17,258 17,048
Schedule of cash and cash equivalents	​ ​ ​ ​ ​ ​ Net cash and cash equivalents ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Other cash equivalents (1) 10,273 17,933 Cash at bank and at hand 1,212 8,985 Bank overdrafts ​ (1,338) ​ — Cash and cash equivalents 10,147 26,918 (1) Other cash equivalents correspond to short-term bank deposits.
Schedule of changes in share capital	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Premiums ​ ​ ​ ​ ​ ​ ​ ​ Share ​ related to ​ Number of ​ Nominal Date Nature of the transactions capital share capital shares value Balance at December 31, 2023 ​ ​ 521,158 201,862,263 52,115,807 0.01 3/25/2024 ​ AGA 2021 & AGA 2021 bis ​ 3,614 ​ (3,614) ​ 361,381 ​ 0.01 Balance at June 30, 2024 ​ ​ ​ 524,772 ​ 201,858,649 ​ 52,477,188 ​ 0.01
Schedule of debt	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Bank borrowings 42,509 27,206 Derivatives instruments ​ 13,569 ​ 10,265 Other loans and similar borrowings (1) 4,302 3,719 Lease liabilities 5,761 6,565 Royalty certificates liabilities ​ 7,263 ​ 6,327 Total debt 73,404 54,082 (1) include accrued interests.
Schedule of movements in the period break down	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 January 1, 2024 54,083 ​ 44,390 Subscription of derivatives instruments (2) ​ 11,809 ​ — Subscription of bank borrowings (1)(2) ​ 13,102 ​ — Subscription of lease liabilities 345 ​ 3,706 Issue of royalty certificates ​ — ​ 5,100 Repayment of bank borrowings (1,177) ​ (2,485) Repayment of lease liabilities (1,173) ​ (1,612) Interests on royalty certificates ​ 936 ​ 1,227 Capitalized interest 3,961 ​ 3,405 Change in fair value of derivatives instruments (2) (8,506) ​ 389 Exchange rate change 24 ​ (38) June 30, 2024 73,404 ​ 54,083
Schedule of valuation approach for BSA arrangement	​ ​ ​ ​ ​ ​ ​ BSA 2022 BSA 2024 Grant date 11/28/2022 ​ 01/04/2024 Expiration date 11/28/2034 ​ 01/04/2036 Number of BSA issued 2,266,023 ​ 3,144,654 Number of shares per BSA 1 ​ 1 Subscription premium price per share (€) 0.01 ​ 0.01 Exercise price per share (€) 4.02 ​ 3.95 Valuation method Longstaff Schwartz ​ Longstaff Schwartz ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of November 28, 2022 ​ ​ ​ EIB Tranche A Warrants ​ (Grant Date) ​ As of December 31, 2023 ​ As of June 30, 2024 Number of BSA outstanding 2,266,023 2,266,023 ​ 2,266,023 ​ Number of shares per BSA ​ 1.00 ​ 1.20 ​ 1.27 ​ Stock price (€) 4.13 4.10 ​ 2.79 ​ Maturity (years) 12 10.9 ​ 10.4 ​ Volatility 68 % 62 % 59.6 % Cap of the put option (m€) 25.0 25.0 ​ 25.0 ​ Risk free rate Euribor 6M Euribor 6M ​ Euribor 6M ​ Expected dividends — — ​ — ​ Fair Value (k€) 9,469 10,266 ​ 6,738 ​ Unit fair value (€) 4.18 4.53 ​ 2.97 ​
Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Retirement benefit obligations ​ 1,555 ​ 1,559 Total obligation 1,555 1,559
Schedule of change in the provision recorded in respect of defined benefit schemes	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Provision at beginning of period (1,559) ​ (1,234) Expense for the period (70) ​ (228) Actuarial gains or losses recognized in other comprehensive income 74 ​ (97) Provision at end of period (1,555) ​ (1,559)
Schedule of expense recognized in the statement of income (loss)	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Service cost for the period (104) (183) Interest cost for the period (25) (46) Benefits for the period 59 — Total (70) (228)
Schedule of maturity of long-term and short-term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ Less than Between Between More than In thousands of euros Total ​ 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 42,509 ​ 3,229 36,164 2,225 890 Derivatives 13,569 ​ — 13,569 — — Other loans ​ 4,302 ​ 42 ​ 4,260 ​ — ​ — Lease liabilities ​ 5,761 ​ 2,455 ​ 3,306 ​ — ​ — Royalty certificates liabilities ​ 7,263 ​ — ​ — ​ — ​ 7,263 Total debt 73,404 ​ 5,726 57,299 2,225 8,153 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dec. 31, 2023 ​ ​ Less than Between Between More than In thousands of euros ​ Total ​ 1 year ​ 1 and 3 years ​ 3 and 5 years ​ 5 years Bank borrowings 27,206 ​ 2,928 4,872 17,848 1,558 Derivatives ​ 10,265 ​ — ​ — ​ 10,265 ​ — Other loans and similar borrowings 3,719 ​ 82 — 3,636 — Lease liabilities ​ 6,565 ​ 2,298 ​ 4,267 ​ — ​ — Royalty certificates liabilities 6,327 ​ — — — 6,327 Total debt 54,082 ​ 5,308 9,140 31,749 7,885
Schedule of trade payables and other current liabilities	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Trade payables ​ 36,583 37,679 Short-term contract liabilities ​ 3 ​ 6 Other current liabilities ​ — — Trade payables and other current liabilities ​ 36,586 37,685
Schedule of trade payables break down by payment	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Due in 30 days ​ 26,217 24,995 Due in 30-60 days ​ 10,362 12,684 Due in more than 60 days ​ 4 — Trade payable ​ 36,583 37,679
Schedule of other current liabilities	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 Dec. 31, 2023 Employee‑related payables 1,739 1,869 Accrued payroll and other employee-related taxes 1,801 1,540 Sales tax payables 2,140 3,569 Other accrued taxes and employee-related expenses 142 164 Other miscellaneous payables 12 23 Other current liabilities 5,834 7,165
Schedule of financial assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ ​ ​ Financial ​ ​ ​ ​ ​ ​ ​ ​ Book value ​ assets/liabilities ​ Financial ​ ​ ​ ​ ​ ​ on the ​ carried at ​ assets ​ Liabilities ​ ​ ​ ​ statement ​ fair value ​ carrieds at ​ carried at ​ ​ ​ ​ of financial ​ through ​ amortized ​ amortized ​ ​ Financial assets position profit or loss cost cost Fair value Long-term accrued income ​ — — — — — Long-term deposit accounts ​ — ​ — ​ — ​ — ​ — Advance payment ​ 1,047 ​ — ​ 1,047 ​ — ​ 1,047 Current accrued income ​ 1,687 — 1,687 — 1,687 Short-term deposit accounts ​ — — — — — Trade receivables ​ 809 ​ — ​ 809 ​ — ​ 809 Other receivables ​ 2,518 — 2,518 — 2,518 Cash and cash equivalents ​ 10,147 — 10,147 — 10,147 Total ​ 16,208 — 16,208 — 16,208 ​ ​ ​ ​ ​ ​ ​ Financial liabilities ​ ​ ​ ​ ​ ​ Long-term debt (1) ​ 46,846 — — 46,846 45,994 Derivative instruments ​ 13,569 13,569 — — 13,569 Royalty certificates liabilities ​ 7,263 ​ — ​ — ​ 7,263 ​ 9,050 Short-term debt ​ 5,726 — — 5,726 5,726 Trade payables ​ 36,583 ​ — ​ — ​ 36,583 ​ 36,583 Other miscellaneous payables ​ 12 ​ — ​ — ​ 12 ​ 12 Total ​ 109,998 ​ 13,569 ​ — ​ 96,429 ​ 110,933 (1) See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dec. 31, 2023 ​ ​ Financial ​ ​ ​ ​ ​ Book Value ​ assets/liabilities ​ Financial ​ ​ ​ ​ ​ ​ on the ​ carried at ​ assets ​ Liabilities ​ ​ ​ ​ statement ​ fair value ​ carrieds at ​ carried at ​ ​ ​ ​ of financial ​ through ​ amortized ​ amortized ​ ​ Financial assets position profit or loss cost cost Fair value Long-term deposit accounts ​ 9,000 — 9,000 — 9,000 Long-term security deposits ​ 8 ​ — ​ 8 ​ — ​ 8 Advance payment ​ 1,047 — 1,047 — 1,047 Short-term deposit accounts ​ 70 ​ — ​ 70 ​ — ​ 70 Trade receivables ​ 3,807 — 3,807 — 3,807 Other receivables ​ 857 — 857 — 857 Cash and cash equivalents ​ 26,918 — 26,918 — 26,918 Total ​ 41,706 — 41,706 — 41,706 ​ ​ ​ ​ ​ ​ ​ Financial liabilities ​ ​ ​ ​ ​ ​ Long-term debt (1) ​ 32,181 — — 32,181 29,701 Derivative instruments ​ 10,265 10,265 — — 10,265 Royalty certificates liabilities ​ 6,327 ​ — ​ — ​ 6,327 ​ 9,617 Short-term debt ​ 5,308 ​ — ​ — ​ 5,308 ​ 5,308 Trade payables ​ 37,679 ​ — ​ — ​ 37,679 ​ 37,679 Other miscellaneous payables ​ 23 ​ — ​ — ​ 23 ​ 23 Total ​ 91,784 ​ 10,265 ​ — ​ 81,518 ​ 92,594 ​
BSPCE share warrants and BSA share warrants
Notes to the interim condensed consolidated statement of financial position
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at Jan 1, ​ ​ ​ ​ ​ Forfeited / ​ at June 30, ​ exercisable Type Grant Date (in euros) 2024 Issued Exercised Lapsed 2024 shares BSPCE - Plan 2021 ​ 04/16/2021 ​ 11.74 ​ 430,000 ​ — ​ — ​ — ​ 430,000 ​ 430,000 TOTAL BSPCE share warrants 430,000 — — — 430,000 430,000 BSA - Plan 2017 05/29/2017 6.68 130,000 — — — 130,000 130,000 BSA - Plan 2018 12/14/2018 6.07 116,000 — — — 116,000 116,000 BSA 2019 06/28/2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 bis ​ 03/09/2020 ​ 3.68 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 ter ​ 03/09/2020 ​ 3.68 ​ 36,000 ​ — ​ — ​ — ​ 36,000 ​ 36,000 BSA 2021 ​ 04/16/2021 ​ 11.74 ​ 14,333 ​ — ​ — ​ — ​ 14,333 ​ 14,333 BSA 2023 ​ 05/25/2023 ​ 2.51 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ — BSA 2023 - 2 ​ 12/15/2023 ​ 3.91 ​ 20,000 ​ ​ ​ ​ ​ ​ ​ 20,000 ​ — TOTAL BSA share warrants 346,333 — — — 346,333 316,333 Total share warrants ​ ​ ​ ​ 776,333 — — — 776,333 746,333
AGA Plan 2023-1
Notes to the interim condensed consolidated statement of financial position
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock price ​ Outstanding ​ ​ ​ ​ ​ ​ ​ Outstanding ​ ​ ​ ​ at grant date ​ at Jan 1, ​ ​ ​ ​ ​ Forfeited / ​ at June 30, Type Grant Date (in euros) 2024 Granted Vested Lapsed 2024 AGA - Plan 2021 - 1 04/16/2021 11.30 297,599 — (296,166) (1,433) — AGA - Plan 2021 - bis 12/08/2021 12.20 65,215 — (65,215) — — AGA 2023-1 05/25/2023 2.60 300,000 300,000 — — 600,000 AGA 2023-2 ​ 12/15/2023 ​ 3.90 ​ 748,000 ​ — ​ — ​ (23,350) ​ 724,650 TOTAL free shares ​ ​ ​ ​ 1,410,814 300,000 (361,381) (24,783) 1,324,650
PAGUP 2023
Notes to the interim condensed consolidated statement of financial position
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	As of January 1, 2024, one performance units plan was outstanding: PAGUP 2023. No performance units award plan has been attributed in the first six months of 2024. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reference Outstanding ​ ​ ​ Outstanding Number of ​ ​ Grant ​ price (in ​ at Jan 1, ​ ​ ​ ​ ​ ​ ​ at June 30, ​ exercisable Type ​ Date ​ euros) ​ 2024 ​ Issued ​ Exercised ​ Convert AGA ​ 2024 ​ shares PAGUP 2023 ​ 05/25/2023 ​ 2.60 ​ 300,000 ​ — ​ — ​ (300,000) ​ — ​ — TOTAL PAGUP ​ ​ ​ ​ ​ 300,000 ​ — ​ — ​ (300,000) ​ — ​ —

Notes to the interim condense_4

Notes to the interim condensed consolidated statement of (income) loss (Tables)	6 Months Ended
	Jun. 30, 2024
Notes to the interim condensed consolidated statement of (income) loss
Schedule of revenues and other income	​ ​ ​ ​ ​ ​ Operating income ​ Six months ended In thousands of euros June 30, 2024 June 30, 2023 Revenue 41 ​ 1,901 Total revenue 41 ​ 1,901 Tax credits 2,630 ​ 3,631 Subsidies 5 ​ 3 Other 58 ​ 1,087 Other income 2,693 ​ 4,721 Total revenue and other income 2,734 ​ 6,622
Schedule of research and development, marketing	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and ​ Marketing – ​ General and ​ ​ Six months ended June 30, 2024 ​ development ​ Business ​ administrative ​ ​ In thousands of euros costs development expenses Total Disposables (887) — — (887) Energy and liquids (447) — — (447) Patents (643) — — (643) Studies (34,073) — — (34,073) Maintenance (526) — — (526) Fees (118) (2) (2,675) (2,795) IT systems (405) (6) (33) (444) Support costs (including taxes) — — (375) (375) Personnel costs (7,637) (153) (2,600) (10,391) Depreciation, amortization and provisions (1,732) — (122) (1,854) Insurances ​ — ​ — ​ (921) ​ (921) Other operating expenses (352) (437) (975) (1,764) Total operating expenses (46,822) (598) (7,701) (55,122) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and ​ Marketing – ​ General and ​ ​ Six months ended June 30, 2023 ​ development ​ Business ​ administrative ​ ​ en milliers d'euros costs development expenses Total Disposables (943) — — (943) Energy and liquids (479) — — (479) Patents (257) — — (257) Studies (42,847) — — (42,847) Maintenance (459) — — (459) Fees (61) — (1,884) (1,945) IT systems (440) (9) (50) (498) Support costs (including taxes) — — (343) (343) Personnel costs (7,065) (126) (2,347) (9,538) Depreciation, amortization and provisions (1,061) — (104) (1,166) Insurances ​ — ​ — ​ (1,121) ​ (1,121) Other operating expenses (450) (570) (964) (1,985) Total operating expenses (54,062) (705) (6,812) (61,580)
Schedule of personnel costs and headcount	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketing - ​ ​ ​ ​ Research and ​ Business ​ General and ​ ​ Six months ended June 30, 2024 ​ development ​ development ​ administrative ​ ​ In thousands of euros ​ costs ​ expenses ​ expenses ​ Total Wages, salaries and similar costs (4,824) (120) (1,237) (6,181) Payroll taxes (1,312) (10) (563) (1,886) Provisions for retirement benefit obligations (51) — (35) (86) Share-based payments (1,450) (24) (765) (2,238) Total personnel costs (7,637) (153) (2,600) (10,391) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketing - ​ ​ ​ ​ Research and ​ Business ​ General and ​ ​ Six months ended June 30, 2023 ​ development ​ development ​ administrative ​ ​ In thousands of euros costs expenses expenses Total Wages, salaries and similar costs (4,399) (104) (1,191) (5,694) Payroll taxes (1,222) (10) (476) (1,708) Provisions for retirement benefit obligations (61) — (29) (90) Share-based payments (1,383) (13) (650) (2,046) Total personnel costs (7,065) (126) (2,347) (9,538)
Schedule of other operating income and expenses	​ ​ ​ ​ ​ ​ ​ Six months ended In thousands of euros June 30, 2024 June 30, 2023 Other operating income ​ 160 ​ — Other operating expenses ​ (22) ​ (44) Other operating income and expenses 138 ​ (44)
Schedule of financial income and expenses	​ ​ ​ ​ ​ ​ ​ Six months ended In thousands of euros June 30, 2024 June 30, 2023 Income from cash equivalents 430 ​ 564 Foreign exchange gains 157 ​ 187 Gain on fair value variation ​ 8,506 ​ 1,623 Total financial income 9,093 ​ 2,373 Interest cost (5,218) ​ (1,941) Foreign exchange losses ​ (323) ​ (683) Other financial expenses (46) ​ (23) Total financial expenses (5,586) ​ (2,646) Net financial income 3,507 ​ (273)
Schedule of share of net profit - Equity method	​ ​ ​ ​ ​ (in thousands of euros) For the period started January 1, 2024, to June 30, 2024 Research and development costs (51) ​ General and administrative expenses (1,475) ​ Net operating loss (1,526) ​ Financial income 20 ​ Financial expenses (3) ​ Net financial income 17 ​ Income (expense) tax — ​ Net loss for the period (1,509) ​ Exchange difference on translation of foreign operations (1,964) ​ Items that will be reclassified subsequently to profit or loss (3,473) ​ Total comprehensive loss (3,473) ​ Group's share in 14.64 % Share of net profit 235 ​ Elimination of downstream sales (66) ​ Share of net profit - Equity method 168 ​
Schedule of basic and diluted loss per share	​ ​ ​ ​ ​ ​ ​ Six months ended ​ June 30, 2024 June 30, 2023 Net loss for the period (49,029) ​ (55,269) Weighted average number of shares outstanding used to calculate basic/diluted loss per share (1) 51,982,093 ​ 42,044,796 Basic/diluted loss per share (0.94) ​ (1.31) (1) In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2024 and 2023

Other financial information (Ta

Other financial information (Tables)	6 Months Ended
	Jun. 30, 2024
Other financial information
Schedule of commitments given and received	​ ​ ​ ​ ​ ​ In thousands of euros June 30, 2024 December 31, 2023 CRO 1 175,461 ​ 183,366 CMO 6,846 ​ 5,733 Lease 7,592 ​ 8,595 Others 20,361 ​ 23,442 Total commitments given 210,261 ​ 221,136 Agreements concerning the provision of facilities 296 ​ 260 Total commitments received 296 ​ 260 1 Including CRO with Pharmaceutical Research Associates B.V.

Company information - (Details)

Company information - (Details) € / shares in Units, $ in Millions

1 Months Ended

6 Months Ended

12 Months Ended

May 16, 2024 item

Mar. 18, 2024 EUR (€) g

Feb. 01, 2024 item

Jan. 18, 2024 EUR (€)

Jan. 04, 2024 EUR (€) shares

Oct. 11, 2023 ¥ / shares

Oct. 11, 2023 € / shares

Jan. 31, 2023 item

Jun. 30, 2024 EUR (€)

Dec. 31, 2022

Jan. 18, 2024 USD ($)

Oct. 18, 2023 EUR (€)

Oct. 18, 2023 USD ($)

Sep. 26, 2023

May 16, 2022 EUR (€)

Collaborative Arrangements

Loan obtained

€ 24,911,000

Total amount of loan | $

$ 25

Finance contract with EIB

Collaborative Arrangements

Loan obtained

€ 25,000,000

Total amount of loan

€ 50,000,000

Finance contract with EIB, first tranche (Tranche A)

Collaborative Arrangements

Loan obtained

€ 25,000,000

Finance contract with EIB, second tranche (Tranche B)

Collaborative Arrangements

Loan obtained

€ 25,000,000

Number of shares underlying in EIB | shares

3,144,654

Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH

Collaborative Arrangements

Maximum duration of Phase III trial

7 years

840 days

Number of Biopsies Under the Phase III trial | item

2

3

Number of weeks under the active treatment extension study

336 days

Licensing agreement with Hepalys

Collaborative Arrangements

Upfront payment receivable

€ 9,500,000

$ 10

Maximum milestone payments receivable | $

$ 231

Licensing agreement with Hepalys | Hepalys Pharma, Inc

Collaborative Arrangements

Percent of acquisition

30%

Purchase of interests in investments accounted for using equity method, price per share | (per share)

¥ 300

€ 1.90

Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease

Collaborative Arrangements

Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy

30%

Daily dose of lanifibranor in trial | g

0.800

Percentage reduction in results on treatments

1.14%

Reduction in hepatic steatosis (in percent)

(47.00%)

Percentage of patients treated in trial

83%

Significant relative reduction in VAT/SAT ratio (in percent)

(5.00%)

Combination of lanifibranor

Collaborative Arrangements

Number of patients in main cohort

63

Daily dose of lanifibranor in trial | g

0.800

Daily dose of empagliflozin in trial | g

0.010

Percentage reduction in results on treatments

1.59%

Reduction in hepatic steatosis (in percent)

(38.00%)

Percentage of patients treated in trial

67%

Significant relative reduction in VAT/SAT ratio (in percent)

(17.00%)

Treatment period under study

168 days

Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D

Collaborative Arrangements

Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy

0%

Percentage of increase observed in the placebo arm

0.26%

Reduction in hepatic steatosis (in percent)

0%

Significant relative reduction in VAT/SAT ratio (in percent)

11%

Number of patients randomized | item

900

Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D | Minimum

Collaborative Arrangements

Number of patients to be treated for 48 weeks | item

360

Number of patients to be treated for 72 weeks | item

80

NATiV3 Phase III clinical trial | Maximum

Collaborative Arrangements

Treatment period under study

504 days

NATiV3 Phase III clinical trial | Minimum

Collaborative Arrangements

Treatment period under study

336 days

Company information - Significa

Company information - Significant events in the first half of 2024 (Details) € / shares in Units, $ in Millions						6 Months Ended
	Mar. 18, 2024	Jan. 18, 2024 EUR (€) shares	Jan. 04, 2024 EUR (€) € / shares shares	Jan. 03, 2024 € / shares	Dec. 08, 2022	Jun. 30, 2024 EUR (€) shares	Mar. 07, 2024 site	Jan. 18, 2024 USD ($)	Dec. 31, 2023 shares	Nov. 28, 2022 shares	May 16, 2022 EUR (€)
Collaborative Arrangements
Notional Amount | $								$ 25
Subscription of borrowings and warrants net of transaction cost						€ 24,911,000
Finance contract with EIB
Collaborative Arrangements
Percentage of share capital held by counterparty if all outstanding warrants are exercised						9.90%
Notional Amount											€ 50,000,000
Subscription of borrowings and warrants net of transaction cost		€ 25,000,000
Finance contract with EIB, first tranche (Tranche A)
Collaborative Arrangements
Subscription of borrowings and warrants net of transaction cost						€ 25,000,000
Number of shares per instrument | shares						1.27			1.20	1
Interest rate					8%
Maturity term after the disbursement of the tranche					4 years
Aggregate amount to be received under the conditions precedent to the EIB Financing		€ 18,000,000
Finance contract with EIB, first tranche (Tranche A) | Financial liabilities at amortized cost
Collaborative Arrangements
Notional Amount						€ 25,000,000
Finance contract with EIB, second tranche (Tranche B)
Collaborative Arrangements
Number of warrants issued | shares		3,144,654	3,144,654
Percentage of company's share capital outstanding, issued as warrants			6.07%
Exercise price of warrant | € / shares			€ 3.95	€ 3.95
Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares				95%
Term of warrants			12 years
Shares issuable upon exercise of warrants | shares			3,144,654
Maximum gross proceeds			€ 12,421,383
Subscription of borrowings and warrants net of transaction cost			€ 25,000,000
Number of shares per instrument | shares			1			1
Interest rate		7%						7%
Maturity term after the disbursement of the tranche		3 years
Aggregate amount to be received under the conditions precedent to the EIB Financing		€ 70,000,000
Minimum upfront payments for out-licensing, partnership or royalty transaction		10,000,000
Finance contract with EIB, second tranche (Tranche B) | Financial liabilities at amortized cost
Collaborative Arrangements
Notional Amount		€ 25,000,000
Warrant agreement with the European Investment Bank
Collaborative Arrangements
Maturity term of warrants			12 years
NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH
Collaborative Arrangements
Number of sites operating under central IRB overseeing | site							152
Percentage of patients randomized in the main cohort							60%
LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]
Collaborative Arrangements
Treatment period under study	168 days
Drawdown of borrowings | Finance contract with EIB, second tranche (Tranche B)
Collaborative Arrangements
Interest rate		7%						7%
Maturity term after the disbursement of the tranche		3 years

Basis of preparation and stat_3

Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024 EUR (€) entity	Dec. 31, 2023
General principles and statement of compliance
Number of entities being consolidated | entity	2
Hepalys Pharma, Inc
General principles and statement of compliance
Proportion of ownership interest	14.64%	15%
Inventiva Inc.
General principles and statement of compliance
Percent of ownership interest	100%
Non-controlling interest | €	€ 0

Basis of preparation and stat_4

Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2024 € / $	Jun. 30, 2023 € / $	Dec. 31, 2023 $ / €
Exchange rate (USD per EUR)
Average exchange rate for the period	1.0813	1.0807	1.0803
Exchange rate at period end	1.0705	1.0866	1.1050

Accounting Principles - Fair va

Accounting Principles - Fair value measurement (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Foreign currency forwards contract
Financial liabilities	€ 109,998	€ 91,784
Financial assets carried at fair value through profit or loss
Foreign currency forwards contract
Financial liabilities	13,569
Level 3 | Financial liabilities carried at fair value through profit or loss
Foreign currency forwards contract
Financial liabilities		10,265
Level 3 | Financial liabilities carried at fair value through profit or loss | Long-term financial debt - derivatives
Foreign currency forwards contract
Financial liabilities	13,569	€ 10,265
Level 3 | Financial assets carried at fair value through profit or loss
Foreign currency forwards contract
Financial liabilities	€ 13,569

Accounting principles - Going c

Accounting principles - Going concern (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Accounting Principles
Cash and cash equivalents	€ 10,147	€ 26,918	€ 31,240	€ 86,736
Bank overdrafts inclusive of cash and cash equivalents	€ 1,338

Notes to the interim condense_5

Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details) € in Thousands	Jun. 30, 2024 EUR (€)
Intangible assets
Balance at the beginning	€ 541
Balance at the end	451
Gross
Intangible assets
Balance at the beginning	3,926
Balance at the end	3,947
Amortization
Intangible assets
Balance at the beginning	(3,384)
Balance at the end	€ (3,496)

Notes to the interim condense_6

Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details) € in Thousands	Jun. 30, 2024 EUR (€)
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	€ 9,125
Balance at the end	7,979
Depreciation and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(10,714)
Balance at the end	(12,396)
Property, plant and equipment in progress | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	19,840
Balance at the end	€ 20,376

Notes to the interim condense_7

Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details) € in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)
Property, Plant and Equipment
Increase in net value of property, plant and equipment	€ 0.5
Amortization
Property, Plant and Equipment
Increases	1.7
Right of use
Property, Plant and Equipment
Increases	1.2
Fibroscan machines
Property, Plant and Equipment
Additions to right-of-use assets	0.4
Increases	€ 0.3

Notes to the interim condense_8

Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details) - Hepalys Pharma, Inc [Member] - EUR (€) € in Millions			6 Months Ended	12 Months Ended
	Jan. 15, 2024	Oct. 11, 2023	Jun. 30, 2024	Dec. 31, 2023
Investments accounted for using the equity method
Number of shares acquired in associate		1,500,000
Capital increase	€ 1.6
Group's share in %	14.60%		14.60%	15%

Notes to the interim condense_9

Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details) - EUR (€)		6 Months Ended		12 Months Ended
	Jan. 15, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Investments accounted for using the equity method
Intangible assets		€ 451,000		€ 541,000
Other current assets		14,554,000		11,696,000
Cash and cash equivalents		10,147,000	€ 31,240,000	26,918,000	€ 86,736,000
Total assets		39,426,000		69,561,000
Capital stock		524,772		521,000
Net loss for the period		(49,029,000)		(110,426,000)
Shareholders' equity		(79,060,000)	(7,667,000)	(32,032,000)	45,476,000
Total non-current liabilities		70,340,000		51,434,000
Trade payables		36,583,000		37,679,000
Other current liabilities		5,834,000		7,165,000
Total current liabilities		48,146,000		50,158,000
Total equity and liabilities		39,426,000		69,561,000
Balance at the beginning		(32,032,000)	45,476,000	45,476,000
Loss for the period		(49,029,000)	(55,269,000)
Balance at the end		(79,060,000)	(7,667,000)	(32,032,000)
Carrying amount		€ 1,131,000		€ 1,425,000
Hepalys Pharma, Inc
Investments accounted for using the equity method
Group's share in %		14.64%		15%
Group's share		€ 2,813,000		€ 3,267,000
Elimination of unrealised profit on downstream sales		(1,718,000)		(1,881,000)
Goodwill		37,000		39,000
Carrying amount		1,131,000		1,425,000
Hepalys Pharma, Inc
Investments accounted for using the equity method
Intangible assets		17,217,000		20,278,000
Total non-current assets		17,217,000		20,278,000
Other current assets		17,000		44,000
Cash and cash equivalents		1,997,000		1,082,000
Total current assets		2,015,000		1,126,000
Deferred assets		2,000		41,000
Total assets		19,233,000		21,444,000
Capital stock		523,000		640,000
Capital reserve		20,379,000		22,655,000
Capital surplus-others		774,000
Earnings brought forward		(1,018,000)		(178,000)
Net loss for the period		(1,444,000)		(1,111,000)
Treasury Shares				(812,000)
Shareholders' equity		19,214,000		21,194,000	€ 22,645,000
Trade payables		7,000		237,000
Other current liabilities		12,000		13,000
Total current liabilities		19,000		250,000
Total equity and liabilities		19,233,000		21,444,000
Balance at the beginning		21,194,000	€ 22,645,000	22,645,000
Loss for the period		(1,509,000)		(879,000)
Other comprehensive income		(1,964,000)		247,000
Capital variations		1,566,000		(819,000)
Balance at the end		€ 19,214,000		€ 21,194,000
Group's share in %	14.60%	14.60%		15%

Notes to the interim condens_10

Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Notes to the interim condensed consolidated statement of financial position
Longterm deposit accounts		€ 9,000
Advance payments - non-current	€ 1,047	1,047
Security deposits		8
Other noncurrent assets	€ 1,047	€ 10,055

Notes to the interim condens_11

Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Other Non Current Assets
Increase (decrease) in long-term deposit accounts	€ 9,000
Long-term deposits	€ 9,000
Period of long-term deposit	2 years
Non-current advances to suppliers	€ 1,047	€ 1,047
Contract CRO with Pharmaceutical Research Associates B.V.
Other Non Current Assets
Non-current advances to suppliers	€ 1,000	€ 1,000

Notes to the interim condens_12

Notes to the interim condensed consolidated statement of financial position - Inventories (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Inventories
Inventories	€ 393	€ 417
Laboratory inventories
Inventories
Inventories	402	426
Inventories write-down
Inventories
Inventories	€ (9)	€ (9)

Notes to the interim condens_13

Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Trade receivables, tax receivables and other current assets
Trade receivables	€ 809	€ 3,807
3 months or less
Trade receivables, tax receivables and other current assets
Trade receivables	€ 809	€ 3,807

Notes to the interim condens_14

Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Trade receivables, tax receivables and other current assets
CIR and other research tax credits receivable	€ 2,657	€ 5,333
Other	47	19
Tax receivables	2,704	5,352
Prepaid expenses	7,039	4,656
Short-term deposit accounts		70
Current accrued income	1,687	1,047
Liquidity agreement - Cash	289	422
Sales tax receivable	3,311	5,066
Other receivables	2,229	435
Other current assets	14,554	11,696
Other current assets and receivables	17,258	€ 17,048
Licensing and collaboration agreement with CTTQ
Trade receivables, tax receivables and other current assets
Current accrued income	€ 2,700

Notes to the interim condens_15

Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details) € in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)
Notes to the interim condensed consolidated statement of financial position
Increase in short-term deposit accounts	€ 2.4
Receivable for current year	2.7
Trade receivables decreased	€ (3)
Average payment period for trade receivables	30 days

Notes to the interim condens_16

Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Notes to the interim condensed consolidated statement of financial position
Other cash equivalents	€ 10,273	€ 17,933
Cash at bank and at hand	1,212	8,985
Bank overdrafts	(1,338)
Cash and cash equivalents	€ 10,147	€ 26,918	€ 31,240	€ 86,736

Notes to the interim condens_17

Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Notes to the interim condensed consolidated statement of financial position
Issued capital	€ 524,772	€ 521,000
Number of fully authorized, subscribed and paid up shares	52,477,188	52,115,807
Nominal value	€ 0.01

Notes to the interim condens_18

Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details) - EUR (€)	Mar. 25, 2024	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Disclosure of classes of share capital [line items]
Shareholders' equity		€ (79,060,000)	€ (32,032,000)	€ (7,667,000)	€ 45,476,000
Number of shares outstanding		52,477,188	52,115,807
Nominal value		€ 0.01
Increase (decrease) in number of shares outstanding	361,381
Share capital
Disclosure of classes of share capital [line items]
Shareholders' equity		€ 524,772	€ 521,158	421,000	421,000
Nominal value	€ 0.01	€ 0.01	€ 0.01
Issue of ordinary shares	€ 3,614
Premiums related to share capital
Disclosure of classes of share capital [line items]
Shareholders' equity		€ 201,858,649	€ 201,862,263	€ 173,886,000	€ 173,886,000
Issue of ordinary shares	€ (3,614)

Notes to the interim condens_19

Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)			12 Months Ended
	Jan. 01, 2024	Jan. 01, 2023	Dec. 31, 2019
Notes to the interim condensed consolidated statement of financial position
Liquidity agreement term	12 months	12 months	12 months

Notes to the interim condens_20

Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details) - € / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
BSA share warrants | Directors
Disclosure of classes of share capital [line items]
Subscription price per share						€ 0.534
BSA share warrants | Service providers
Disclosure of classes of share capital [line items]
Subscription price per share					€ 0.48
BSA share warrants | David Nikodem
Disclosure of classes of share capital [line items]
Subscription price per share		€ 2.45	€ 0.29	€ 0.18
BSA 2023 plan | David Nikodem
Disclosure of classes of share capital [line items]
Subscription price per share	€ 0.20
Exercise price	2.51
BSA- 2 2023 plan | David Nikodem
Disclosure of classes of share capital [line items]
Subscription price per share	0.31
Exercise price	€ 3.91

Notes to the interim condens_21

Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)		6 Months Ended
	Mar. 25, 2024 shares	Jun. 30, 2024 shares € / shares
Notes to the interim condensed consolidated statement of financial position
Issued | shares	300,000
Outstanding, Ending balance | shares		0
BSPCE and BSA Share Warrants
Notes to the interim condensed consolidated statement of financial position
Outstanding, Beginning balance		776,333
Outstanding, Ending balance		776,333
Number of exercisable shares		746,333
BSPCE plans
Notes to the interim condensed consolidated statement of financial position
Outstanding, Beginning balance		430,000
Outstanding, Ending balance		430,000
Number of exercisable shares		430,000
BSPCE 2021
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 11.74
Outstanding, Beginning balance		430,000
Outstanding, Ending balance		430,000
Number of exercisable shares		430,000
BSA plans
Notes to the interim condensed consolidated statement of financial position
Outstanding, Beginning balance		346,333
Outstanding, Ending balance		346,333
Number of exercisable shares		316,333
Number of share warrants outstanding | shares		430,000
BSA - 2017 plan
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 6.68
Outstanding, Beginning balance		130,000
Outstanding, Ending balance		130,000
Number of exercisable shares		130,000
BSA - 2018 plan
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 6.07
Outstanding, Beginning balance		116,000
Outstanding, Ending balance		116,000
Number of exercisable shares		116,000
BSA 2019
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 2.20
Outstanding, Beginning balance		10,000
Outstanding, Ending balance		10,000
Number of exercisable shares		10,000
BSA 2019 bis
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 3.68
Outstanding, Beginning balance		10,000
Outstanding, Ending balance		10,000
Number of exercisable shares		10,000
BSA 2019 ter
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 3.68
Outstanding, Beginning balance		36,000
Outstanding, Ending balance		36,000
Number of exercisable shares		36,000
BSA 2021
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 11.74
Outstanding, Beginning balance		14,333
Outstanding, Ending balance		14,333
Number of exercisable shares		14,333
BSA 2023 plan
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 2.51
Outstanding, Beginning balance		10,000
Outstanding, Ending balance		10,000
BSA- 2 2023 plan
Notes to the interim condensed consolidated statement of financial position
Exercise price (in euros)		€ 3.91
Outstanding, Beginning balance		20,000
Outstanding, Ending balance		20,000

Notes to the interim condens_22

Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)		6 Months Ended
	Mar. 25, 2024 shares	Jun. 30, 2024 EUR (€) shares € / shares	Jun. 30, 2023 EUR (€)	Jan. 01, 2024 plan
Notes to the interim condensed consolidated statement of financial position
Number of plans attributed		0
Issued	300,000
Outstanding, Ending balance		0
Capital increase arising from the vesting of bonus share awards | €		€ 2,238,000	€ 2,046,000
Expense from share-based payment transactions | €		€ 2,200,000
Bonus share award plans
Notes to the interim condensed consolidated statement of financial position
Outstanding, Beginning balance		1,410,814
Issued		300,000
Exercised/Vesting		(361,381)
Forfeited/ Lapsed		(24,783)
Outstanding, Ending balance		1,324,650
AGA 2021-1
Notes to the interim condensed consolidated statement of financial position
Stock price at grant date (in euros) | € / shares		€ 11.30
Outstanding, Beginning balance		297,599
Exercised/Vesting		(296,166)
Forfeited/ Lapsed		(1,433)
AGA 2021-bis
Notes to the interim condensed consolidated statement of financial position
Stock price at grant date (in euros) | € / shares		€ 12.20
Outstanding, Beginning balance		65,215
Exercised/Vesting		(65,215)
AGA Plan 2023-1
Notes to the interim condensed consolidated statement of financial position
Stock price at grant date (in euros) | € / shares		€ 2.60
Outstanding, Beginning balance		300,000
Issued		300,000
Outstanding, Ending balance		600,000
Expense from share-based payment transactions | €			€ 2,000,000
AGA 2023-2
Notes to the interim condensed consolidated statement of financial position
Stock price at grant date (in euros) | € / shares		€ 3.90
Outstanding, Beginning balance		748,000
Forfeited/ Lapsed		(23,350)
Outstanding, Ending balance		724,650
PAGUP
Notes to the interim condensed consolidated statement of financial position
Number of award plans outstanding | plan				1
Number of plans attributed		0
Outstanding, Beginning balance		300,000
Forfeited/ Lapsed		(300,000)
PAGUP 2023
Notes to the interim condensed consolidated statement of financial position
Stock price at grant date (in euros) | € / shares		€ 2.60
Outstanding, Beginning balance		300,000
Forfeited/ Lapsed		(300,000)
PAGUP 2023 | Frederic Cren [Member]
Notes to the interim condensed consolidated statement of financial position
Number of shares converted	300,000
Instruments lapsed	300,000
AGA 2021 & AGA 2021 bis
Notes to the interim condensed consolidated statement of financial position
Exercised/Vesting		(361,381)
Capital increase arising from the vesting of bonus share awards | €		€ 3,613.81

Notes to the interim condens_23

Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Notes to the interim condensed consolidated statement of financial position
Bank borrowings	€ 42,509	€ 27,206
Derivatives instruments	13,569	10,265
Other loans and similar borrowings	4,302	3,719
Lease liabilities	5,761	6,565
Royalty certificates liabilities	7,263	6,327
Total debt	€ 73,404	€ 54,083	€ 44,390

Disclosure - Notes to the inter

Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Notes to the interim condensed consolidated statement of financial position
Beginning balance	€ 54,083	€ 44,390
Subscription of derivatives instruments	11,809
Subscription of bank borrowings	13,102
Subscription of lease liabilities	345	3,706
Issue of royalty certificates		5,100
Repayment of lease liabilities	(1,173)	(1,612)
Issue of royalty certificates	936	1,227
Repayment of bank borrowings	(1,177)	(2,485)
Capitalized interests	3,961	3,405
Change in fair value of derivatives instruments	(8,506)	389
Exchange rate change	24	(38)
Ending balance	€ 73,404	€ 54,083

Notes to the interim condens_24

Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan ("PGE") and equity recovery loans ("PPR") (Details) € in Thousands, $ in Millions		1 Months Ended			6 Months Ended		12 Months Ended
	Jan. 18, 2024 EUR (€)	May 31, 2023	Jun. 30, 2022 EUR (€) loan	May 31, 2020 EUR (€) agreement	Jun. 30, 2024 EUR (€)	Jun. 30, 2023 EUR (€)	Dec. 31, 2022	Jan. 18, 2024 USD ($)
Guarantee Details
Loan obtained					€ 24,911
Total amount of loan | $								$ 25
Repayments of borrowings					1,177	€ 1,448
Loan agreements with syndicate of French banks, under stimulus economic plan
Guarantee Details
Number of loan agreements | loan			2
Total amount of loan			€ 5,300
Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)
Guarantee Details
Number of loan agreements | loan			1
Percentage of loan guaranteed by French state							90%
Equity recovery loans
Guarantee Details
Financing period of loan		8 years
Repayment period for loan		4 years
Financing from a syndicate of French banks
Guarantee Details
Number of loans obtained guaranteed by the french state | agreement				3
Loan obtained				€ 10,000
Extension of term of debt				4 years
Number of loan agreements | loan			3
Repayments of borrowings					€ 1,200
Licensing and collaboration agreement with CTTQ [Member]
Guarantee Details
Amount invoiced to counterparty for milestone payment	€ 25,000

Notes to the interim condens_25

Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details) € in Thousands, $ in Millions				6 Months Ended
	Jan. 18, 2024 EUR (€)	Dec. 08, 2022	May 16, 2022 EUR (€) tranche	Jun. 30, 2024 EUR (€)	Jan. 18, 2024 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)
Financial debt
Notional amount | $					$ 25
Borrowings				€ 73,404		€ 54,083	€ 44,390
Financial liabilities, at fair value				110,933		92,594
Finance contract with EIB
Financial debt
Notional amount			€ 50,000
Number of equal tranches | tranche			2
Notional amount per tranche			€ 25,000
Capitalized interest				4,000
Finance contract with EIB, Tranche A
Financial debt
Interest rate		8%
Maturity term after the disbursement of the tranche		4 years
Finance contract with EIB, Tranche A | Financial liabilities at amortized cost
Financial debt
Notional amount				25,000
Borrowings				€ 21,100		€ 15,400
Borrowings, effective interest rate				21.90%		21.90%
Borrowing costs				€ 100
Finance contract with EIB, Tranche A | Financial liabilities at fair value
Financial debt
Actualization rate				22.90%
Financial liabilities, at fair value				€ 20,600
Finance contract with EIB, Tranche B
Financial debt
Interest rate	7%				7%
Maturity term after the disbursement of the tranche	3 years
Finance contract with EIB, Tranche B | Financial liabilities at amortized cost
Financial debt
Notional amount	€ 25,000
Borrowings				€ 15,000
Borrowings, effective interest rate				32.70%
Borrowing costs	€ 100
Finance contract with EIB, Tranche B | Financial liabilities at fair value
Financial debt
Actualization rate				33.20%
Financial liabilities, at fair value				€ 14,700

Notes to the interim condens_26

Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)					6 Months Ended	12 Months Ended
	Mar. 25, 2024 shares	Jan. 04, 2024 EUR (€) € / shares shares	Nov. 28, 2022 EUR (€) D € / shares shares	Jul. 01, 2022 € / shares shares	Jun. 30, 2024 EUR (€) shares € / shares	Dec. 31, 2023 EUR (€) shares	Jan. 03, 2024 € / shares
Disclosure of detailed information about borrowings [line items]
Number of equity instruments granted	300,000
Finance contract with EIB, Tranche A
Disclosure of detailed information about borrowings [line items]
Number of BSA outstanding			2,266,023		2,266,023	2,266,023
Number of shares per instrument			1		1.27	1.20
Stock price (€)			4.13		2.79	4.10
Maturity (years)			12 years		10 years 4 months 24 days	10 years 10 months 24 days
Volatility			68%		59.60%	62%
Cap of the put option (m€)			25		25	25
Fair Value (k€) | €			€ 9,469,000		€ 6,738,000	€ 10,266,000
Unit fair value			0.0418		0.0297	0.0453
Finance contract with EIB, Tranche B
Disclosure of detailed information about borrowings [line items]
Percentage of company's share capital outstanding, issued as warrants		6.07%
Exercise price of warrant | € / shares		€ 3.95					€ 3.95
Number of BSA outstanding		3,144,654			3,144,654
Number of shares per instrument		1			1
Stock price (€) | € / shares		4.12			2.79
Maturity (years)		12 years			11 years 6 months
Volatility		62%			59.60%
Cap of the put option (m€)		25			25
Fair Value (k€) | €		€ 11,809,000			€ 6,830,000
Unit fair value | €		0.0376			0.0217
BSA 2022
Disclosure of detailed information about borrowings [line items]
Number of equity instruments granted					2,266,023
Subscription premium price per share (€) | € / shares					€ 0.01
Exercise price (in euros) | € / shares					€ 4.02
Number of shares per instrument					1
BSA 2024 [Member]
Disclosure of detailed information about borrowings [line items]
Number of equity instruments granted					3,144,654
Subscription premium price per share (€) | € / shares					€ 0.01
Exercise price (in euros) | € / shares					€ 3.95
Number of shares per instrument					1
Warrant agreement with the European Investment Bank
Disclosure of detailed information about borrowings [line items]
Term over which volume weighted average price per share to determine number of warrants to be issued				180 days
Maturity term of warrants		12 years
Warrant agreement with the European Investment Bank | Ordinary shares
Disclosure of detailed information about borrowings [line items]
Number of shares per instrument						1.20
Warrant agreement with the European Investment Bank | Derivatives
Disclosure of detailed information about borrowings [line items]
Threshold trading days of warrants | D			90
Subscription premium price per share (€) | € / shares				€ 0.01
Maturity term of warrants				12 years
Number of shares per AGA				1
Warrant agreement with the European Investment Bank | Derivatives | Finance contract with EIB, Tranche A
Disclosure of detailed information about borrowings [line items]
Number of warrants issued			2,266,023
Percentage of company's share capital outstanding, issued as warrants			4.70%
Exercise price of warrant | € / shares			€ 4.0152
Maximum potential gross proceeds from exercise of warrants | €			€ 9,100,000
Transaction costs on issue of warrants | €			€ 56,000
Warrant agreement with the European Investment Bank | Derivatives | Finance contract with EIB, Tranche B
Disclosure of detailed information about borrowings [line items]
Number of warrants issued		3,144,654
Percentage of company's share capital outstanding, issued as warrants		5.20%
Exercise price of warrant | € / shares		€ 3.95
Maximum potential gross proceeds from exercise of warrants | €		€ 12,400,000
Transaction costs on issue of warrants | €		€ 90,000

Notes to the interim condens_27

Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Disclosure of detailed information about borrowings [line items]
Lease liabilities	€ 5,761	€ 6,565
Increase (decrease) in lease liabilities		€ (800)
Fibroscan machines
Disclosure of detailed information about borrowings [line items]
Additions to right-of-use assets	€ 400
Minimum | Fibroscan machines
Disclosure of detailed information about borrowings [line items]
Lease term	3 years
Maximum | Fibroscan machines
Disclosure of detailed information about borrowings [line items]
Lease term	4 years
Lease liabilities | Minimum
Disclosure of detailed information about borrowings [line items]
Interest rate	1.89%
Lease liabilities | Maximum
Disclosure of detailed information about borrowings [line items]
Interest rate	5.18%

Notes to the interim condens_28

Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about borrowings [line items]
Bank borrowings	€ 42,509	€ 27,206
Derivatives	13,569	10,265
Other loans and similar borrowings	4,302	3,719
Lease liabilities	5,761	6,565
Royalty certificates liabilities	7,263	6,327
Total debt	73,404	54,083	€ 44,390
Less than 1 year
Disclosure of detailed information about borrowings [line items]
Bank borrowings	3,229	2,928
Other loans and similar borrowings	42	82
Lease liabilities	2,455	2,298
Total debt	5,726	5,308
Between 1 and 3 years
Disclosure of detailed information about borrowings [line items]
Bank borrowings	36,164	4,872
Derivatives	13,569
Other loans and similar borrowings	4,260
Lease liabilities	3,306	4,267
Total debt	57,299	9,140
Between 3 and 5 years
Disclosure of detailed information about borrowings [line items]
Bank borrowings	2,225	17,848
Derivatives		10,265
Other loans and similar borrowings		3,636
Total debt	2,225	31,749
More than 5 years
Disclosure of detailed information about borrowings [line items]
Bank borrowings	890	1,558
Royalty certificates liabilities	7,263	6,327
Total debt	€ 8,153	€ 7,885

Notes to the interim condens_29

Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details) € in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)	Jan. 18, 2024 USD ($)	Dec. 31, 2023 EUR (€)	Aug. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)
Disclosure of detailed information about borrowings [line items]
Financial liabilities	€ 109,998		€ 91,784
Borrowings	73,404		54,083		€ 44,390
Notional Amount | $		$ 25
Financial liabilities, at fair value	€ 110,933		92,594
Royalty certificates liabilities
Disclosure of detailed information about borrowings [line items]
Royalty certificates, effective interest rate	31.90%
Borrowings	€ 7,300		€ 6,300
Financial liabilities, at fair value	€ 9,100
Discount rate, measurement input [member] | Royalty certificates liabilities
Disclosure of detailed information about borrowings [line items]
Significant unobservable input, liabilities	27.9
Royalty Certificate Liabilities [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings				€ 5,100
Notional Amount				€ 5,100

Notes to the interim condens_30

Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Notes to the interim condensed consolidated statement of financial position
Provisions	€ 0	€ 0
Retirement benefit obligations	1,555	1,559
Total Obligation	€ 1,555	€ 1,559	€ 1,234

Notes to the interim condens_31

Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Notes to the interim condensed consolidated statement of financial position
At beginning of period	€ (1,559)	€ (1,234)
Expense for the period	(70)	(228)
Actuarial gains or losses recognized in other comprehensive income	74	(97)
At end of period	€ (1,555)	€ (1,559)

Notes to the interim condens_32

Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Notes to the interim condensed consolidated statement of financial position
Service cost for the period	€ (104)	€ (183)
Interest cost for the period	(25)	(46)
Benefits for the period	59
Total	€ (70)	€ (228)

Notes to the interim condens_33

Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Notes to the interim condensed consolidated statement of financial position
Employeerelated payables	€ 1,739	€ 1,869
Accrued payroll and other employeerelated taxes	1,801	1,540
VAT payables	2,140	3,569
Other accrued taxes and employeerelated expenses	142	164
Other miscellaneous payables	12	23
Other current liabilities	€ 5,834	€ 7,165

Notes to the interim condens_34

Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Trade Payable And Other Current Liabilities [Line Items]
Other non-current liabilities	€ 1,032	€ 1,032
Licensing and collaboration agreement with CTTQ
Trade Payable And Other Current Liabilities [Line Items]
Other non-current liabilities	€ 1,000	€ 1,000

Notes to the interim condens_35

Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Notes to the interim condensed consolidated statement of financial position
Trade payables	€ 36,583	€ 37,679
Short-term contract liabilities	3	6
Other current liabilities	5,834	7,165
Trade payables and other current liabilities	36,586	€ 37,685
Accrued expenses	24,000
Accrued liabilities relating to scientific projects	€ 20,200

Notes to the interim condens_36

Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Trade Payable And Other Current Liabilities [Line Items]
Trade payable	€ 36,583	€ 37,679
Increase in trade accounts payable	(1,100)
Due in 30 days
Trade Payable And Other Current Liabilities [Line Items]
Trade payable	26,217	24,995
Due in 30-60 days
Trade Payable And Other Current Liabilities [Line Items]
Trade payable	10,362	€ 12,684
Due in more than 60 days
Trade Payable And Other Current Liabilities [Line Items]
Trade payable	€ 4

Notes to the interim condens_37

Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Financial assets and liabilities
Financial assets	€ 16,208	€ 41,706
Financial liabilities	109,998	91,784
Financial assets, at fair value	16,208	41,706
Financial liabilities, at fair value	110,933	92,594
Liabilities carried at amortized cost
Financial assets and liabilities
Financial liabilities		81,518
Long-term debt
Financial assets and liabilities
Financial liabilities	46,846	32,181
Financial liabilities, at fair value	45,994	29,701
Long-term debt | Liabilities carried at amortized cost
Financial assets and liabilities
Financial liabilities	46,846	32,181
Derivative instruments
Financial assets and liabilities
Financial liabilities	13,569	10,265
Financial liabilities, at fair value	13,569	10,265
Royalty certificates liabilities
Financial assets and liabilities
Financial liabilities	7,263	6,327
Financial liabilities, at fair value	9,050	9,617
Royalty certificates liabilities | Liabilities carried at amortized cost
Financial assets and liabilities
Financial liabilities		6,327
Short-term debt
Financial assets and liabilities
Financial liabilities	5,726	5,308
Financial liabilities, at fair value	5,726	5,308
Short-term debt | Liabilities carried at amortized cost
Financial assets and liabilities
Financial liabilities	5,726	5,308
Trade payables
Financial assets and liabilities
Financial liabilities	36,583	37,679
Financial liabilities, at fair value	36,583	37,679
Trade payables | Liabilities carried at amortized cost
Financial assets and liabilities
Financial liabilities		37,679
Other miscellaneous payables
Financial assets and liabilities
Financial liabilities	12	23
Financial liabilities, at fair value	12	23
Other miscellaneous payables | Liabilities carried at amortized cost
Financial assets and liabilities
Financial liabilities		23
Financial assets carried at amortized cost
Financial assets and liabilities
Financial assets	16,208
Financial liabilities	96,429	10,265
Financial assets carried at amortized cost | Derivative instruments
Financial assets and liabilities
Financial liabilities		10,265
Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets		41,706
Financial liabilities	13,569
Long-term deposit accounts
Financial assets and liabilities
Financial assets		9,000
Financial assets, at fair value		9,000
Long-term deposit accounts | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets		9,000
Long-term security deposits
Financial assets and liabilities
Financial assets		8
Financial assets, at fair value		8
Long-term security deposits | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets		8
Advance payment
Financial assets and liabilities
Financial assets	1,047	1,047
Financial assets, at fair value	1,047	1,047
Advance payment | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets	1,047	1,047
Current accrued income
Financial assets and liabilities
Financial assets	1,687
Financial assets, at fair value	1,687
Current accrued income | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets	1,687
Short-term deposit accounts
Financial assets and liabilities
Financial assets		70
Financial assets, at fair value		70
Short-term deposit accounts | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets		70
Trade receivables
Financial assets and liabilities
Financial assets	809	3,807
Financial assets, at fair value	809	3,807
Trade receivables | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets	809	3,807
Other receivables
Financial assets and liabilities
Financial assets	2,518	857
Financial assets, at fair value	2,518	857
Other receivables | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets	2,518	857
Cash and cash equivalents
Financial assets and liabilities
Financial assets	10,147	26,918
Financial assets, at fair value	10,147	26,918
Cash and cash equivalents | Financial assets carried at fair value through profit or loss
Financial assets and liabilities
Financial assets	€ 10,147	€ 26,918

Notes to the interim condens_38

Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Notes to the interim condensed consolidated statement of (income) loss
Revenue	€ 41	€ 1,901
Total revenue	41	1,901
Tax Credits	2,630	3,631
Subsidies	5	3
Other	58	1,087
Other income	2,693	4,721
Total revenues and other income	€ 2,734	€ 6,622

Notes to the interim condens_39

Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Notes to the income statement
Tax credits of current year	€ 2,700
Tax research credit	2,657		€ 5,333
Tax income	119	€ (7)
Inventiva Inc.
Notes to the income statement
Tax research credit	1,000
Tax income	800
Licensing and collaboration agreement with CTTQ
Notes to the income statement
Reinvoicing of share of costs incurred included in other income	€ 2,600	300
Service contract with Avant Sante [Member]
Notes to the income statement
Reinvoicing of specific costs related to CRO accrued liabilities included in other income		€ 700

Notes to the interim condens_40

Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating expenses
Disposables	€ (887)	€ (943)
Energy and liquids	(447)	(479)
Patents	(643)	(257)
Studies	(34,073)	(42,847)
Maintenance	(526)	(459)
Fees	(2,795)	(1,945)
IT systems	(444)	(498)
Support costs (including taxes)	(375)	(343)
Personnel costs	(10,391)	(9,538)
Depreciation, amortization and provisions	(1,854)	(1,166)
Insurances	(921)	(1,121)
Other operating expenses	(1,764)	(1,985)
Total operating expenses	(55,122)	(61,580)
Research and development costs
Operating expenses
Disposables	(887)	(943)
Energy and liquids	(447)	(479)
Patents	(643)	(257)
Studies	(34,073)	(42,847)
Maintenance	(526)	(459)
Fees	(118)	(61)
IT systems	(405)	(440)
Personnel costs	(7,637)	(7,065)
Depreciation, amortization and provisions	(1,732)	(1,061)
Other operating expenses	(352)	(450)
Total operating expenses	(46,822)	(54,062)
Marketing - Business development expenses
Operating expenses
Fees	(2)
IT systems	(6)	(9)
Personnel costs	(153)	(126)
Other operating expenses	(437)	(570)
Total operating expenses	(598)	(705)
General and administrative expenses
Operating expenses
Fees	(2,675)	(1,884)
IT systems	(33)	(50)
Support costs (including taxes)	(375)	(343)
Personnel costs	(2,600)	(2,347)
Depreciation, amortization and provisions	(122)	(104)
Insurances	(921)	(1,121)
Other operating expenses	(975)	(964)
Total operating expenses	€ (7,701)	€ (6,812)

Notes to the interim condens_41

Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details) € in Thousands	6 Months Ended
	Jun. 30, 2024 EUR (€) employee	Jun. 30, 2023 EUR (€) employee
Operating expenses
Number of employees | employee	123	117
Wages, salaries and similar costs	€ (6,181)	€ (5,694)
Payroll taxes	(1,886)	(1,708)
Provisions for retirement benefit obligations	(86)	(90)
Share-based payments	(2,238)	(2,046)
Total personnel costs	€ (10,391)	€ (9,538)
Inventiva S.A [Member]
Operating expenses
Number of employees | employee	112	105
Inventiva Inc [Member]
Operating expenses
Number of employees | employee	11	12
Research and development costs
Operating expenses
Wages, salaries and similar costs	€ (4,824)	€ (4,399)
Payroll taxes	(1,312)	(1,222)
Provisions for retirement benefit obligations	(51)	(61)
Share-based payments	(1,450)	(1,383)
Total personnel costs	(7,637)	(7,065)
Marketing - Business development expenses
Operating expenses
Wages, salaries and similar costs	(120)	(104)
Payroll taxes	(10)	(10)
Share-based payments	(24)	(13)
Total personnel costs	(153)	(126)
General and administrative expenses
Operating expenses
Wages, salaries and similar costs	(1,237)	(1,191)
Payroll taxes	(563)	(476)
Provisions for retirement benefit obligations	(35)	(29)
Share-based payments	(765)	(650)
Total personnel costs	€ (2,600)	€ (2,347)

Notes to the interim condens_42

Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Notes to the interim condensed consolidated statement of (income) loss
Other operating income	€ 160
Other operating expenses	(22)	€ (44)
Other operating income and expenses	€ 138	€ (44)

Notes to the interim condens_43

Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Notes to the interim condensed consolidated statement of (income) loss
Income from cash equivalents	€ 430	€ 564
Foreign exchange gains	157	187
Gain on fair value variation	8,506	1,623
Total financial income	9,093	2,373
Interest cost	(5,218)	(1,941)
Foreign exchange losses	(323)	(683)
Other financial expenses	(46)	(23)
Total financial expenses	(5,586)	(2,646)
Net financial income	3,507	€ (273)
Fair value of the EIB warrants	€ 8,500

Notes to the interim condens_44

Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details) - EUR (€) € in Thousands		6 Months Ended		12 Months Ended
	Jan. 15, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Investments accounted for using the equity method
Research and development costs		€ (46,822)	€ (54,062)
General and administrative expenses		(7,701)	(6,812)
Net operating loss		(52,249)	(55,003)
Financial income		9,093	2,373
Financial expenses		(5,586)	(2,646)
Net financial income		3,507	(273)
Income tax		(119)	7
Net loss for the period		(49,029)	(55,269)
Exchange difference on translation of foreign operations		66	104
Items that will be reclassified subsequently to profit or loss		(220)	104
Items that will not be reclassified subsequently to profit or loss		74	(14)
Total comprehensive loss		(49,175)	€ (55,179)
Share of net profit - Equity method		€ (168)
Hepalys Pharma, Inc
Investments accounted for using the equity method
Group's share in %		14.64%		15%
Share of net profit		€ 235
Elimination of downstream sales		(66)
Share of net profit - Equity method		168
Hepalys Pharma, Inc
Investments accounted for using the equity method
Research and development costs		(51)
General and administrative expenses		(1,475)
Net operating loss		(1,526)
Financial income		20
Financial expenses		(3)
Net financial income		17
Net loss for the period		(1,509)		€ (879)
Exchange difference on translation of foreign operations		(1,964)
Items that will be reclassified subsequently to profit or loss		(3,473)
Total comprehensive loss		€ (3,473)
Group's share in %	14.60%	14.60%		15%

Notes to the interim condens_45

Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details) - EUR (€) € in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2024
Notes to the interim condensed consolidated statement of (income) loss
Projected tax rate			0%
Current taxes	€ 0
Tax income	€ 119	€ (7)

Notes to the interim condens_46

Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Notes to the interim condensed consolidated statement of (income) loss
Net loss for the period	€ (49,029)	€ (55,269)
Weighted average number of shares outstanding used to calculate basic loss per share	51,982,093	42,044,796
Weighted average number of shares outstanding used to calculate diluted loss per share	51,982,093	42,044,796
Basic loss per share	€ (0.94)	€ (1.31)
Diluted loss per share	€ (0.94)	€ (1.31)

Other financial information (De

Other financial information (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Apr. 30, 2021
Other financial information [line items]
Total commitments given	€ 210,261	€ 221,136
Agreements concerning the provision of facilities	296	260
Total commitments received	296	260
Contract CRO with Pharmaceutical Research Associates B.V.
Other financial information [line items]
Total commitments given	158,600
Amount committed to pay			€ 13,300
CRO
Other financial information [line items]
Total commitments given	175,461	183,366
CMO
Other financial information [line items]
Total commitments given	6,846	5,733
Lease
Other financial information [line items]
Total commitments given	7,592	8,595
Other
Other financial information [line items]
Total commitments given	20,361	€ 23,442
Pharmaceutical Research Associates
Other financial information [line items]
Total commitments given	254,300
Pharmaceutical Research Associates | Minimum
Other financial information [line items]
Bonus or malus capped amount	700
Pharmaceutical Research Associates | Maximum
Other financial information [line items]
Bonus or malus capped amount	3,400
CTTQ
Other financial information [line items]
Amount committed to pay	€ 20,200

Other financial information - E

Other financial information - Events after the reporting date (Details)				1 Months Ended	6 Months Ended	12 Months Ended
	Oct. 14, 2024 EUR (€) € / shares shares	Oct. 11, 2024 EUR (€)	Jul. 18, 2024 EUR (€)	Jan. 31, 2023	Jun. 30, 2024 EUR (€) € / shares shares	Dec. 31, 2022	Jul. 05, 2024	Dec. 31, 2023 shares	Nov. 28, 2022 shares
Events after the reporting date
Par value of share | € / shares					€ 0.01
Finance contract with EIB, first tranche (Tranche A)
Events after the reporting date
Number of shares per warrant | shares					1.27			1.20	1
Finance contract with EIB, first tranche (Tranche A) | Warrant agreement with the European Investment Bank
Events after the reporting date
Number of shares underlying in EIB | shares					1.27
Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH
Events after the reporting date
Maximum duration of Phase III trial				7 years		840 days
Presentation of results from study | NATiV3 Phase III clinical trial
Events after the reporting date
Percentage of patients in trial, enrolled in main cohort							80%
Percentage of patients in trial, enrolled in exploratory cohort							100%
Issuance of royalty certificates
Events after the reporting date
Number of royalty certificates issued			201
Gross cash proceeds			€ 20,100,000
Annual royalty percentage			3%
Maximum duration of Phase III trial			14 years
Financing agreement in three phases
Events after the reporting date
Number of equal tranches					3
Aggregate amount to be received either in exchange for new shares or warrants					€ 348,000,000
Issuance of shares without preferential subscription rights
Events after the reporting date
Stock issued during period	€ 94,100,000
Number of shares issued during the period | shares	34,600,507
Par value of share | € / shares	€ 0.01
Number of warrants granted | shares	35,399,481
Number of shares per warrant | shares	1
Issuance of shares or warrants without preferential subscription rights
Events after the reporting date
Stock issued during period	€ 21,400,000
Par value of share | € / shares	€ 0.01
Issuance of shares or warrants subject to conditions
Events after the reporting date
Stock issued during period	€ 116,000,000
Exercise price of warrant | € / shares	€ 1.50
Class of warrant or right, value of number of securities	€ 116,000,000
Financing through fund raising | Licensing and collaboration agreement with CTTQ
Events after the reporting date
Minimum amount committed for fund raising		€ 180,000,000
Financing through fund raising | Licensing and collaboration agreement with CTTQ | First tranche
Events after the reporting date
Amount received on licensing arrangements		€ 10,000,000
Received from settlement		30 days
Financing through fund raising | Licensing and collaboration agreement with CTTQ | Second tranche
Events after the reporting date
Amount received on licensing arrangements		€ 10,000,000
Financing through fund raising | Licensing and collaboration agreement with CTTQ | Third tranche upon publication of pivotal data
Events after the reporting date
Amount received on licensing arrangements		€ 10,000,000